BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. The Lancet Oncology 2015;16:1090-8. [DOI: 10.1016/s1470-2045(15)00040-6] [Cited by in Crossref: 990] [Cited by in F6Publishing: 408] [Article Influence: 165.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen X, Zhang W, Qian D, Guan Y, Wang Y, Zhang H, Er P, Yan C, Li Y, Ren X, Pang Q, Wang P. Chemoradiotherapy-Induced CD4+ and CD8+ T-Cell Alterations to Predict Patient Outcomes in Esophageal Squamous Cell Carcinoma. Front Oncol 2019;9:73. [PMID: 30828566 DOI: 10.3389/fonc.2019.00073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Guo X, Fang W, Li Z, Yu Z, Rong T, Fu J, Han Y, Tan L, Chen C, Liu S, Liao Y, Xiao G, Wei Y, Zhu C, Li H, Luo J, Xing W. Adjuvant radiotherapy, chemotherapy or surgery alone for high-risk histological node negative esophageal squamous cell carcinoma: Protocol for a multicenter prospective randomized controlled trial. Thorac Cancer 2018;9:1801-6. [PMID: 30276974 DOI: 10.1111/1759-7714.12882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Khalafi S, Lockhart AC, Livingstone AS, El-Rifai W. Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet? Cancers (Basel) 2020;12:E3077. [PMID: 33105560 DOI: 10.3390/cancers12113077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Triantafyllou T, Wijnhoven B. Multidisciplinary treatment of esophageal cancer: The role of active surveillance after neoadjuvant chemoradiation. Ann Gastroenterol Surg 2020;4:352-9. [PMID: 32724878 DOI: 10.1002/ags3.12350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Simonsen C, Thorsen-Streit S, Sundberg A, Djurhuus SS, Mortensen CE, Qvortrup C, Pedersen BK, Svendsen LB, de Heer P, Christensen JF. Effects of high-intensity exercise training on physical fitness, quality of life and treatment outcomes after oesophagectomy for cancer of the gastro-oesophageal junction: PRESET pilot study. BJS Open 2020;4:855-64. [PMID: 32856785 DOI: 10.1002/bjs5.50337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Inderson A, Slingerland M, Farina Sarasqueta A, de Steur WO, Boonstra JJ. EUS-guided radiofrequency ablation for a left adrenal oligometastasis of an esophageal adenocarcinoma. VideoGIE 2018;3:159-61. [PMID: 29916497 DOI: 10.1016/j.vgie.2018.03.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
7 Simoni N, Pavarana M, Micera R, Weindelmayer J, Mengardo V, Rossi G, Cenzi D, Tomezzoli A, Del Bianco P, Giacopuzzi S, De Manzoni G, Mazzarotto R. Long-Term Outcomes of Induction Chemotherapy Followed by Chemo-Radiotherapy as Intensive Neoadjuvant Protocol in Patients with Esophageal Cancer. Cancers (Basel) 2020;12:E3614. [PMID: 33287147 DOI: 10.3390/cancers12123614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Malouff TD, Mahajan A, Krishnan S, Beltran C, Seneviratne DS, Trifiletti DM. Carbon Ion Therapy: A Modern Review of an Emerging Technology. Front Oncol 2020;10:82. [PMID: 32117737 DOI: 10.3389/fonc.2020.00082] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 42.0] [Reference Citation Analysis]
9 Murimwa G, Hester C, Mansour JC, Polanco PM, Porembka MR, Wang SC, Zeh HJ Jr, Yopp AC. Comparative Outcomes of Adenosquamous Carcinoma of the Gallbladder: an Analysis of the National Cancer Database. J Gastrointest Surg 2021;25:1815-27. [PMID: 32705618 DOI: 10.1007/s11605-020-04729-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Song T, Yao Q, Qu J, Zhang H, Zhao Y, Qin J, Feng W, Zhang S, Han X, Wang S, Yan X, Li H. The value of intravoxel incoherent motion diffusion-weighted imaging in predicting the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma. Eur Radiol 2021;31:1391-400. [PMID: 32901300 DOI: 10.1007/s00330-020-07248-z] [Reference Citation Analysis]
11 Faiz Z, Huijgen LJW, Alqethami HJ, Burgerhof JGM, Kats-Ugurlu G, Plukker JTM. Prevalence and Prognostic Significance of Extramural Venous Invasion in Patients with Locally Advanced Esophageal Cancer. Ann Surg Oncol 2018;25:1588-97. [PMID: 29611027 DOI: 10.1245/s10434-018-6448-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Dreyfuss AD, Barsky AR, Wileyto EP, Eads JR, Kucharczuk JC, Williams NN, Karasic TB, Metz JM, Ben-Josef E, Plastaras JP, Wojcieszynski AP. The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer. Cancer Med 2021;10:1275-88. [PMID: 33474812 DOI: 10.1002/cam4.3724] [Reference Citation Analysis]
13 Kaul P, Garg PK. Redefining the Treatment Endpoints in Oncology. Oncologist 2021;26:e521. [PMID: 33484041 DOI: 10.1002/onco.13688] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Nagaki Y, Motoyama S, Sato Y, Wakita A, Fujita H, Sasaki Y, Imai K, Minamiya Y. SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. World J Surg Oncol 2021;19:105. [PMID: 33836789 DOI: 10.1186/s12957-021-02208-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Zhao J, Lei T, Zhang T, Chen X, Dong J, Guan Y, Wang J, Wei H, Er P, Han D, Wei X, Guo Z, Du Q, Wang J, Liu N, Song Y, Yuan Z, Zhao L, Zhang W, Pang Q, Wang P. The efficacy and safety of simultaneous integrated dose reduction in clinical target volume with intensity-modulated radiotherapy for patients with locally advanced esophageal squamous cell carcinoma. Ann Transl Med 2020;8:1160. [PMID: 33241009 DOI: 10.21037/atm-20-4366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Xie CY, Hu YH, Ho JW, Han LJ, Yang H, Wen J, Lam KO, Wong IY, Law SY, Chiu KW, Fu JH, Vardhanabhuti V. Using Genomics Feature Selection Method in Radiomics Pipeline Improves Prognostication Performance in Locally Advanced Esophageal Squamous Cell Carcinoma-A Pilot Study. Cancers (Basel) 2021;13:2145. [PMID: 33946826 DOI: 10.3390/cancers13092145] [Reference Citation Analysis]
17 Hou TC, Dai KY, Wu MC, Hua KL, Tai HC, Huang WC, Chen YJ. Bio-physic constraint model using spatial registration of delta 18F-fluorodeoxyglucose positron emission tomography/computed tomography images for predicting radiation pneumonitis in esophageal squamous cell carcinoma patients receiving neoadjuvant chemoradiation. Onco Targets Ther 2019;12:6439-51. [PMID: 31496743 DOI: 10.2147/OTT.S205803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
18 Gabiatti CTB, Martins MCL, Miyazaki DL, Silva LP, Lascala F, Macedo LT, Mendes MCS, Carvalheira JBC. Myosteatosis in a systemic inflammation-dependent manner predicts favorable survival outcomes in locally advanced esophageal cancer. Cancer Med 2019;8:6967-76. [PMID: 31571402 DOI: 10.1002/cam4.2593] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
19 Kauppila JH, Ohtonen P, Karttunen TJ, Kokkola A, Laine S, Rantanen T, Ristimäki A, Räsänen JV, Saarnio J, Sihvo E, Toikkanen V, Tyrväinen T. Finnish National Esophago-Gastric Cancer Cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland. BMJ Open 2019;9:e024094. [PMID: 30782726 DOI: 10.1136/bmjopen-2018-024094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Noordman BJ, Wijnhoven BPL, Lagarde SM, Boonstra JJ, Coene PPLO, Dekker JWT, Doukas M, van der Gaast A, Heisterkamp J, Kouwenhoven EA, Nieuwenhuijzen GAP, Pierie JEN, Rosman C, van Sandick JW, van der Sangen MJC, Sosef MN, Spaander MCW, Valkema R, van der Zaag ES, Steyerberg EW, van Lanschot JJB; SANO-study group. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer 2018;18:142. [PMID: 29409469 DOI: 10.1186/s12885-018-4034-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 21.7] [Reference Citation Analysis]
21 Chen X, Liu H, Li G, Yu J. Implications of clinical research on adjuvant chemotherapy for gastric cancer: Where to go next? Chin J Cancer Res 2019;31:892-900. [PMID: 31949391 DOI: 10.21147/j.issn.1000-9604.2019.06.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Xu X, Sun ZY, Wu HW, Zhang CP, Hu B, Rong L, Chen HY, Xie HY, Wang YM, Lin HP, Bai YR, Ye Q, Ma XM. Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2021;16:132. [PMID: 34281566 DOI: 10.1186/s13014-021-01852-z] [Reference Citation Analysis]
23 Fassan M, Cavallin F, Guzzardo V, Kotsafti A, Scarpa M, Cagol M, Chiarion-Sileni V, Maria Saadeh L, Alfieri R, Castagliuolo I, Rugge M, Castoro C, Scarpa M. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus. Cancer Med 2019;8:6036-48. [PMID: 31429521 DOI: 10.1002/cam4.2359] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
24 Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer 2018;21:1004-13. [PMID: 29730720 DOI: 10.1007/s10120-018-0832-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
25 Kuo YH, Chien YW, Chen PR, Feng CL, Li CC, Chien CR. Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia. World J Surg Oncol 2019;17:222. [PMID: 31856840 DOI: 10.1186/s12957-019-1712-7] [Reference Citation Analysis]
26 Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, Hamilton EG, Yang YD, Lovejoy A, Newman AM, Kurtz DM, Jin M, Schroers-Martin J, Stehr H, Liu CL, Hui AB, Patel V, Maru D, Lin SH, Alizadeh AA, Diehn M. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology 2020;158:494-505.e6. [PMID: 31711920 DOI: 10.1053/j.gastro.2019.10.039] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 20.0] [Reference Citation Analysis]
27 Harrington C, Smith L, Bisland J, López González E, Jamieson N, Paterson S, Stanley AJ. Mediastinal node staging by positron emission tomography-computed tomography and selective endoscopic ultrasound with fine needle aspiration for patients with upper gastrointestinal cancer: Results from a regional centre. World J Gastrointest Endosc 2018;10:37-44. [PMID: 29375740 DOI: 10.4253/wjge.v10.i1.37] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Creemers A, Ebbing EA, Hooijer GKJ, Stap L, Jibodh-Mulder RA, Gisbertz SS, van Berge Henegouwen MI, van Montfoort ML, Hulshof MCCM, Krishnadath KK, van Oijen MGH, Bijlsma MF, Meijer SL, van Laarhoven HWM. The dynamics of HER2 status in esophageal adenocarcinoma. Oncotarget 2018;9:26787-99. [PMID: 29928485 DOI: 10.18632/oncotarget.25507] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
29 Pelc Z, Skórzewska M, Rawicz-Pruszyński K, Polkowski WP. Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatment-Oncological and Surgical Perspective. Cancers (Basel) 2021;13:2509. [PMID: 34065596 DOI: 10.3390/cancers13102509] [Reference Citation Analysis]
30 Martin-Richard M, Díaz Beveridge R, Arrazubi V, Alsina M, Galan Guzmán M, Custodio AB, Gómez C, Muñoz FL, Pazo R, Rivera F. SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol 2016;18:1179-86. [PMID: 27900538 DOI: 10.1007/s12094-016-1577-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
31 Gu YM, Zhuo Y, Chen LQ, Yuan Y. The Clinical Application of Neoantigens in Esophageal Cancer. Front Oncol 2021;11:703517. [PMID: 34386424 DOI: 10.3389/fonc.2021.703517] [Reference Citation Analysis]
32 Li J, Ma S. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer. Thorac Cancer 2021;12:2293-9. [PMID: 34254738 DOI: 10.1111/1759-7714.14069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Leszczynska KB, Dobrynin G, Leslie RE, Ient J, Boumelha AJ, Senra JM, Hawkins MA, Maughan T, Mukherjee S, Hammond EM. Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer. Radiother Oncol 2016;121:232-8. [PMID: 27839769 DOI: 10.1016/j.radonc.2016.10.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
34 Busslinger GA, Lissendorp F, Franken IA, van Hillegersberg R, Ruurda JP, Clevers H, de Maat MFG. The potential and challenges of patient-derived organoids in guiding the multimodality treatment of upper gastrointestinal malignancies. Open Biol 2020;10:190274. [PMID: 32259456 DOI: 10.1098/rsob.190274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
35 Zhou F, Zhu M, Wang M, Qiu L, Cheng L, Jia M, Xiang J, Wei Q. Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy. J Transl Med. 2016;14:154. [PMID: 27246611 DOI: 10.1186/s12967-016-0903-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
36 Zhang Y, Wang J, Dai N, Han P, Li J, Zhao J, Yuan W, Zhou J, Zhou F. Alteration of plasma metabolites associated with chemoradiosensitivity in esophageal squamous cell carcinoma via untargeted metabolomics approach. BMC Cancer 2020;20:835. [PMID: 32878621 DOI: 10.1186/s12885-020-07336-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
37 Meng X, Wang L, Zhao Y, Zhu B, Sun T, Zhang T, Gu X, Zheng Z. Neoadjuvant Chemoradiation Treatment for Resectable Esophago-Gastric Cancer: A Systematic Review and Meta-Analysis. J Cancer 2019;10:192-204. [PMID: 30662540 DOI: 10.7150/jca.25915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
38 Ko JMY, Ng HY, Lam KO, Chiu KWH, Kwong DLW, Lo AWI, Wong JC, Lin RCW, Fong HCH, Li JYK, Dai W, Law S, Lung ML. Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma. Cancers (Basel) 2020;12:E1352. [PMID: 32466419 DOI: 10.3390/cancers12061352] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1249-1260. [PMID: 28784312 DOI: 10.1016/s1470-2045(17)30447-3] [Cited by in Crossref: 100] [Cited by in F6Publishing: 44] [Article Influence: 25.0] [Reference Citation Analysis]
40 Milito P, Chmelo J, Dunn L, Kamarajah SK, Madhavan A, Wahed S, Immanuel A, Griffin SM, Phillips AW. Chyle Leak Following Radical En Bloc Esophagectomy with Two-Field Nodal Dissection: Predisposing Factors, Management, and Outcomes. Ann Surg Oncol 2021;28:3963-72. [PMID: 33263829 DOI: 10.1245/s10434-020-09399-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Onitilo AA, Stankowski-Drengler TJ, Shiyanbola O, Engel J, Tanimu S, Fagbemi SO, Li YH. Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC). Clin Med Res 2021;19:64-71. [PMID: 33789952 DOI: 10.3121/cmr.2021.1573] [Reference Citation Analysis]
42 de Man FM, van Eerden RAG, Oomen-de Hoop E, Veraart JN, van Doorn N, van Doorn L, van der Gaast A, Mathijssen RHJ. Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients. Cancers (Basel) 2019;11:E826. [PMID: 31200588 DOI: 10.3390/cancers11060826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Zhang C, Shi Z, Kalendralis P, Whybra P, Parkinson C, Berbee M, Spezi E, Roberts A, Christian A, Lewis W, Crosby T, Dekker A, Wee L, Foley KG. Prediction of lymph node metastases using pre-treatment PET radiomics of the primary tumour in esophageal adenocarcinoma: an external validation study. Br J Radiol 2021;94:20201042. [PMID: 33264032 DOI: 10.1259/bjr.20201042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Lopez A, Harada K, Chen HC, Bhutani MS, Weston B, Lee JH, Maru DM, Chin FW, Rogers JE, Thomas I, Amlashi FG, Blum-Murphy MA, Rice DC, Zhao M, Hofstetter WL, Nguyen Q, Ajani JA. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore) 2020;99:e19295. [PMID: 32118743 DOI: 10.1097/MD.0000000000019295] [Reference Citation Analysis]
45 Dinneen K, Baird AM, Ryan C, Sheils O. The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma. Front Mol Biosci 2021;8:600373. [PMID: 33628765 DOI: 10.3389/fmolb.2021.600373] [Reference Citation Analysis]
46 Li H, Fang W, Yu Z, Mao Y, Chen L, He J, Rong T, Chen C, Chen H, Chen K, Du M, Han Y, Hu J, Fu J, Hou X, Gong T, Li Y, Liu J, Liu S, Tan L, Tian H, Wang Q, Xiang J, Xu M, Ye X, You B, Zhang R, Zhao Y; Society of Esophageal Tumor, Chinese Anti-Cancer Association. Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition). J Thorac Dis 2018;10:2481-9. [PMID: 29850156 DOI: 10.21037/jtd.2018.03.175] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
47 Wang Q, Wang F, Lv J, Xin J, Xie L, Zhu W, Tang Y, Li Y, Zhao X, Wang Y, Li X, Guo X. Interactive online consensus survival tool for esophageal squamous cell carcinoma prognosis analysis. Oncol Lett 2019;18:1199-206. [PMID: 31423180 DOI: 10.3892/ol.2019.10440] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
48 Farnes I, Johnson E, Johannessen HO. Management of gastric conduit retention following hybrid and minimally invasive esophagectomy for esophageal cancer: Two retrospective case series. Int J Surg Case Rep. 2017;41:505-510. [PMID: 29546028 DOI: 10.1016/j.ijscr.2017.11.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Wang D, Nagle PW, Wang HH, Smit JK, Faber H, Baanstra M, Karrenbeld A, Chiu RK, Plukker JTM, Coppes RP. Hedgehog Pathway as a Potential Intervention Target in Esophageal Cancer. Cancers (Basel) 2019;11:E821. [PMID: 31200527 DOI: 10.3390/cancers11060821] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
50 Haefner MF, Lang K, Verma V, Koerber SA, Uhlmann L, Debus J, Sterzing F. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity. Radiat Oncol 2017;12:131. [PMID: 28810885 DOI: 10.1186/s13014-017-0863-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
51 Garg PK, Sharma J, Jakhetiya A, Goel A, Gaur MK. Preoperative therapy in locally advanced esophageal cancer. World J Gastroenterol. 2016;22:8750-8759. [PMID: 27818590 DOI: 10.3748/wjg.v22.i39.8750] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
52 Borggreve AS, Goense L, van Rossum PSN, Heethuis SE, van Hillegersberg R, Lagendijk JJW, Lam MGEH, van Lier ALHMW, Mook S, Ruurda JP, van Vulpen M, Voncken FEM, Aleman BMP, Bartels-Rutten A, Ma J, Fang P, Musall BC, Lin SH, Meijer GJ. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using 18F-FDG PET/CT and DW-MRI: A Prospective Multicenter Study. Int J Radiat Oncol Biol Phys 2020;106:998-1009. [PMID: 31987972 DOI: 10.1016/j.ijrobp.2019.12.038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
53 Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048. [PMID: 28748917 DOI: 10.1038/nrdp.2017.48] [Cited by in Crossref: 249] [Cited by in F6Publishing: 215] [Article Influence: 62.3] [Reference Citation Analysis]
54 Vollenbrock SE, Voncken FEM, van Dieren JM, Lambregts DMJ, Maas M, Meijer GJ, Goense L, Mook S, Hartemink KJ, Snaebjornsson P, Ter Beek LC, Verheij M, Aleman BMP, Beets-Tan RGH, Bartels-Rutten A. Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer. Br J Surg 2019;106:596-605. [PMID: 30802305 DOI: 10.1002/bjs.11094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
55 Qiu B, Li J, Wang B, Wang Z, Liang Y, Cai P, Chen Z, Liu M, Fu J, Yang H, Liu H. Adjuvant Therapy for a Microscopically Incomplete Resection Margin after an Esophagectomy for Esophageal Squamous Cell Carcinoma. J Cancer 2017;8:249-57. [PMID: 28243329 DOI: 10.7150/jca.16409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
56 Brown AM, Giugliano DN, Berger AC, Pucci MJ, Palazzo F. Surgical approaches to adenocarcinoma of the gastroesophageal junction: the Siewert II conundrum. Langenbecks Arch Surg. 2017;402:1153-1158. [PMID: 28803334 DOI: 10.1007/s00423-017-1610-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
57 Yap W, Chang Y, Hsieh C, Chao Y, Chen C, Shih M, Hung T. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging 2018;45:689-98. [DOI: 10.1007/s00259-017-3901-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
58 Lee F, Sarkaria IS, Luketich JD. Surgeon proficiency and outcomes in esophagectomy: a perspective and comment on an analysis of the Swedish Cancer Registry. J Thorac Dis 2017;9:E279-81. [PMID: 28449520 DOI: 10.21037/jtd.2017.02.92] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Oliver JA, Venkat P, Frakes JM, Klapman J, Harris C, Montilla-Soler J, Dhadham GC, Altazi BA, Zhang GG, Moros EG, Shridhar R, Hoffe SE, Latifi K. Fiducial markers coupled with 3D PET/CT offer more accurate radiation treatment delivery for locally advanced esophageal cancer. Endosc Int Open 2017;5:E496-504. [PMID: 28573183 DOI: 10.1055/s-0043-104861] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
60 Yuan Y, Ma G, Hu X, Huang Q. Evaluating the eighth edition TNM staging system for esophageal cancer among patients receiving neoadjuvant therapy: A SEER study. Cancer Med 2020;9:4648-55. [PMID: 32391623 DOI: 10.1002/cam4.2997] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Li ZG, Zhang XB, Wen YW, Liu YH, Chao YK. Incidence and Predictors of Unsuspected Recurrent Laryngeal Nerve Lymph Node Metastases After Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma. World J Surg 2018;42:2485-92. [PMID: 29380005 DOI: 10.1007/s00268-018-4516-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Wang T, Yu J, Liu M, Chen Y, Zhu C, Lu L, Wang M, Min L, Liu X, Zhang X, Gubat JA, Chen Y. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies. Drug Des Devel Ther 2019;13:539-53. [PMID: 30787595 DOI: 10.2147/DDDT.S189514] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
63 Schirren R, Novotny A, Friess H, Reim D. Histopathologic Response Is a Positive Predictor of Overall Survival in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany. Cancers (Basel) 2020;12:E2244. [PMID: 32796715 DOI: 10.3390/cancers12082244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
64 Radhakrishna N, Sudha SP, Kalayarasan R, Penumadu P. Does Radiation Dose to Gastric Fundus during Neoadjuvant Chemoradiotherapy for Esophageal Carcinoma Have an Impact on Postoperative Anastomotic Leak? Gastrointest Tumors 2021;8:121-7. [PMID: 34307310 DOI: 10.1159/000513929] [Reference Citation Analysis]
65 Solomon D, Abbas M, Feferman Y, Haddad R, Perl G, Kundel Y, Morgenstern S, Menasherov N, Kashtan H. Signet Ring Cell Features are Associated with Poor Response to Neoadjuvant Treatment and Dismal Survival in Patients with High-Grade Esophageal Adenocarcinoma. Ann Surg Oncol 2021;28:4929-40. [PMID: 33709175 DOI: 10.1245/s10434-021-09644-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
66 Spiegelberg L, van Hoof SJ, Biemans R, Lieuwes NG, Marcus D, Niemans R, Theys J, Yaromina A, Lambin P, Verhaegen F, Dubois LJ. Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity. Radiother Oncol. 2019;141:247-255. [PMID: 31431383 DOI: 10.1016/j.radonc.2019.06.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
67 Kamarajah SK, Navidi M, Wahed S, Immanuel A, Hayes N, Griffin SM, Phillips AW. Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction. Ann Surg Oncol 2020;27:3182-92. [PMID: 32201923 DOI: 10.1245/s10434-020-08358-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Valkema MJ, van der Wilk BJ, Eyck BM, Wijnhoven BPL, Spaander MCW, Doukas M, Lagarde SM, Schreurs WMJ, Roef MJ, van Lanschot JJB, Valkema R. Surveillance of Clinically Complete Responders Using Serial 18F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy. J Nucl Med 2021;62:486-92. [PMID: 32887759 DOI: 10.2967/jnumed.120.247981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Ishikawa T, Yasuda T, Okayama T, Dohi O, Yoshida N, Kamada K, Uchiyama K, Takagi T, Konishi H, Shiozaki A, Fujiwara H, Konishi H, Naito Y, Teramukai S, Itoh Y. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study. Cancer Sci 2019;110:3754-60. [PMID: 31646714 DOI: 10.1111/cas.14218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Chen KN, Gao S, Liu L, He J, Jiang GN, He J. Thoracic Surgeons' Insights: Improving Thoracic Surgery Outcomes During the Coronavirus Disease 2019 Pandemic. Ann Thorac Surg 2020;110:349-52. [PMID: 32507411 DOI: 10.1016/j.athoracsur.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Lin CH, Hung TM, Chang YC, Hsieh CH, Shih MC, Huang SM, Yang CK, Chang CF, Chan SC, Yap WK. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy. Cancers (Basel) 2020;12:E607. [PMID: 32155748 DOI: 10.3390/cancers12030607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Rhodin KE, Raman V, Jawitz OK, Voigt SL, Farrow NE, Harpole DH, Tong BC, D'Amico TA. Patterns of Use of Induction Therapy for T2N0 Esophageal Cancer. Ann Thorac Surg 2021;111:440-7. [PMID: 32681837 DOI: 10.1016/j.athoracsur.2020.05.089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
73 Fan M, Dai L, Yan W, Yang Y, Lin Y, Chen K. Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer. Thorac Cancer 2021;12:2182-8. [PMID: 34137505 DOI: 10.1111/1759-7714.14054] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Jezerskyte E, Saadeh LM, Hagens ERC, Sprangers MAG, Noteboom L, van Laarhoven HWM, Eshuis WJ, van Berge Henegouwen MI, Gisbertz SS. Long-Term Quality of Life After Total Gastrectomy Versus Ivor Lewis Esophagectomy. World J Surg 2020;44:838-48. [PMID: 31732762 DOI: 10.1007/s00268-019-05281-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
75 Ochi M, Murakami Y, Nishibuchi I, Kubo K, Imano N, Takeuchi Y, Kimura T, Hamai Y, Emi M, Okada M, Nagata Y. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma. J Radiat Res 2021;62:142-8. [PMID: 33392619 DOI: 10.1093/jrr/rraa110] [Reference Citation Analysis]
76 Zhang W, Wang P, Pang Q. Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review. Ann Transl Med 2020;8:1193. [PMID: 33241042 DOI: 10.21037/atm-20-4625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Goetze OT, Al-Batran SE, Chevallay M, Mönig SP. Multimodal treatment in locally advanced gastric cancer. Updates Surg 2018;70:173-9. [PMID: 29946806 DOI: 10.1007/s13304-018-0539-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
78 Lee CC, Yeo CM, Ng WK, Verma A, Tey JC. T4 cervical esophageal cancer cured with modern chemoradiotherapy: A case report. World J Clin Cases 2020;8:1950-7. [PMID: 32518786 DOI: 10.12998/wjcc.v8.i10.1950] [Reference Citation Analysis]
79 Hagens ERC, Feenstra ML, Eshuis WJ, Hulshof MCCM, van Laarhoven HWM, van Berge Henegouwen MI, Gisbertz SS. Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. Br J Surg 2020;107:1053-61. [PMID: 32017047 DOI: 10.1002/bjs.11476] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
80 Shi Z, Traverso A, van Soest J, Dekker A, Wee L. Technical Note: Ontology-guided radiomics analysis workflow (O-RAW). Med Phys 2019;46:5677-84. [PMID: 31580484 DOI: 10.1002/mp.13844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
81 Lavery A, Turkington RC. Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer. Gastroenterol Rep (Oxf) 2020;8:411-24. [PMID: 33442473 DOI: 10.1093/gastro/goaa065] [Reference Citation Analysis]
82 Kingma BF, de Maat MFG, van der Horst S, van der Sluis PC, Ruurda JP, van Hillegersberg R. Robot-assisted minimally invasive esophagectomy (RAMIE) improves perioperative outcomes: a review. J Thorac Dis 2019;11:S735-42. [PMID: 31080652 DOI: 10.21037/jtd.2018.11.104] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
83 Ai D, Chen Y, Liu Q, Zhang J, Deng J, Zhu H, Ren W, Zheng X, Li Y, Wei S, Ye J, Zhou J, Lin Q, Luo H, Cao J, Li J, Huang G, Wu K, Fan M, Yang H, Zhu Z, Zhao W, Li L, Fan J, Badakhshi H, Zhao K. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2). BMJ Open 2018;8:e020785. [PMID: 30344165 DOI: 10.1136/bmjopen-2017-020785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
84 Warren GW. Mitigating the adverse health effects and costs associated with smoking after a cancer diagnosis. Transl Lung Cancer Res 2019;8:S59-66. [PMID: 31211106 DOI: 10.21037/tlcr.2019.04.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Kastelowitz N, Marsh MD, McCarter M, Meguid RA, Bhardwaj NW, Mitchell JD, Weyant MJ, Scott C, Schefter T, Stumpf P, Leong S, Messersmith W, Lieu C, Leal AD, Davis SL, Purcell WT, Kane M, Wani S, Shah R, Hammad H, Edmundowicz S, Goodman KA. Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers. Front Oncol 2021;11:614640. [PMID: 33777751 DOI: 10.3389/fonc.2021.614640] [Reference Citation Analysis]
86 Sihag S, Nobel T, Hsu M, Torre S, Tan KS, Janjigian YY, Ku GY, Tang LH, Wu AJ, Maron SB, Bains MS, Jones DR, Molena D. Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter? Ann Surg 2020. [PMID: 33214465 DOI: 10.1097/SLA.0000000000004638] [Reference Citation Analysis]
87 Wu Y, Chen J, Zhao L, Li Q, Zhu J, Yang H, Guo S, Xi M. Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers. Cancer Res Treat 2021;53:172-83. [PMID: 32898941 DOI: 10.4143/crt.2020.594] [Reference Citation Analysis]
88 Akin EA, Qazi ZN, Osman M, Zeman RK. Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review. Abdom Radiol (NY) 2020;45:1018-35. [PMID: 32152644 DOI: 10.1007/s00261-020-02447-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
89 Burke AM, Yeh C, Kim S, Bergquist P, Krishnan P, Barac A, Srichai MB, Unger K. A Prospective Study of Early Radiation Associated Cardiac Toxicity Following Neoadjuvant Chemoradiation for Distal Esophageal Cancer. Front Oncol 2020;10:1169. [PMID: 32903617 DOI: 10.3389/fonc.2020.01169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
90 Reynolds JV, Preston SR, O'Neill B, Baeksgaard L, Griffin SM, Mariette C, Cuffe S, Cunningham M, Crosby T, Parker I, Hofland K, Hanna G, Svendsen LB, Donohoe CL, Muldoon C, O'Toole D, Johnson C, Ravi N, Jones G, Corkhill AK, Illsley M, Mellor J, Lee K, Dib M, Marchesin V, Cunnane M, Scott K, Lawner P, Warren S, O'Reilly S, O'Dowd G, Leonard G, Hennessy B, Dermott RM. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer 2017;17:401. [PMID: 28578652 DOI: 10.1186/s12885-017-3386-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 19.3] [Reference Citation Analysis]
91 Goense L, van Rossum PSN, Xi M, Maru DM, Carter BW, Meijer GJ, Ho L, van Hillegersberg R, Hofstetter WL, Lin SH. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma. Ann Surg Oncol 2018;25:1598-607. [PMID: 29569125 DOI: 10.1245/s10434-018-6435-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
92 Rahman SA, Walker RC, Lloyd MA, Grace BL, van Boxel GI, Kingma BF, Ruurda JP, van Hillegersberg R, Harris S, Parsons S, Mercer S, Griffiths EA, O'Neill JR, Turkington R, Fitzgerald RC, Underwood TJ; OCCAMS Consortium. Machine learning to predict early recurrence after oesophageal cancer surgery. Br J Surg 2020;107:1042-52. [PMID: 31997313 DOI: 10.1002/bjs.11461] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
93 Atay SM, Blum M, Sepesi B. Adjuvant chemotherapy following trimodality therapy for esophageal carcinoma-Is the evidence sufficient? J Thorac Dis 2017;9:3626-9. [PMID: 29268359 DOI: 10.21037/jtd.2017.09.68] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
94 Christensen JF, Simonsen C, Banck-Petersen A, Thorsen-Streit S, Herrstedt A, Djurhuus SS, Egeland C, Mortensen CE, Kofoed SC, Kristensen TS, Garbyal RS, Pedersen BK, Svendsen LB, Højman P, de Heer P. Safety and feasibility of preoperative exercise training during neoadjuvant treatment before surgery for adenocarcinoma of the gastro-oesophageal junction. BJS Open 2019;3:74-84. [PMID: 30734018 DOI: 10.1002/bjs5.50110] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
95 Engel S, Awerbuch A, Kwon D, Picado O, Yechieli R, Yakoub D, Portelance L. Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer: a meta-analysis. J Gastrointest Oncol 2019;10:391-9. [PMID: 31183187 DOI: 10.21037/jgo.2019.01.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
96 Murakami Y, Hamai Y, Emi M, Hihara J, Imano N, Takeuchi Y, Takahashi I, Nishibuchi I, Kimura T, Okada M, Nagata Y. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma. J Radiat Res 2018;59:616-24. [PMID: 29939306 DOI: 10.1093/jrr/rry047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
97 Fornaro L, Spallanzani A, de Vita F, D'Ugo D, Falcone A, Lorenzon L, Tirino G, Cascinu S; GAIN (GAstric Cancer Italian Network). Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers (Basel) 2021;13:1304. [PMID: 33804024 DOI: 10.3390/cancers13061304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res 2017;6:501. [PMID: 28491289 DOI: 10.12688/f1000research.10794.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 Matsunaga T, Miyata H, Sugimura K, Motoori M, Asukai K, Yanagimoto Y, Yamamoto K, Akita H, Nishimura J, Wada H, Takahashi H, Yasui M, Omori T, Ohue M, Fujiwara Y, Yano M. Prognostic Significance of C-reactive Protein-to-prealbumin Ratio in Patients with Esophageal Cancer. Yonago Acta Med 2020;63:8-19. [PMID: 32158328 DOI: 10.33160/yam.2020.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Helminen O, Mrena J, Sihvo E. Benchmark values for transthoracic esophagectomy are not set as the defined "best possible"-a validation study. J Thorac Dis 2018;10:4085-93. [PMID: 30174852 DOI: 10.21037/jtd.2018.06.86] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
101 Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol 2015;17:996-1004. [PMID: 26691658 DOI: 10.1007/s12094-015-1456-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
102 Choi Y, Choi JY, Hong TH, Choi YL, Oh D, Woo SY, Shim YM, Zo JI, Kim HK, Lee KS. Trimodality therapy for locally advanced esophageal squamous cell carcinoma: the role of volume-based PET/CT in patient management and prognostication. Eur J Nucl Med Mol Imaging 2021. [PMID: 34365522 DOI: 10.1007/s00259-021-05487-w] [Reference Citation Analysis]
103 Wang HH, Plukker JTM, Hospers GAP. ASO Author Reflections: Pathologic Complete Response of Extended CROSS Criteria Patients with Esophageal Cancer. Ann Surg Oncol 2021;28:3961-2. [PMID: 33284429 DOI: 10.1245/s10434-020-09438-x] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
104 Ten Kate FJC, van Olphen SH, Bruno MJ, Wijnhoven BPL, van Lanschot JJB, Looijenga LHJ, Fitzgerald RC, Biermann K. Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma. Br J Surg 2017;104:1327-37. [PMID: 28692180 DOI: 10.1002/bjs.10553] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
105 Anap YS, Tanawade PK, Mathankar MJ, Mane-Patil AD, Bagul KG, Pawar RS, Pawar SB. Preoperative Chemoradiation in Locally-Advanced Resectable Carcinoma of the Esophagus in a Single Rural Cancer Hospital in Western India. South Asian J Cancer 2020;9:158-62. [PMID: 33937138 DOI: 10.1055/s-0041-1723075] [Reference Citation Analysis]
106 Koemans WJ, Larue RTHM, Kloft M, Ruisch JE, Compter I, Riedl RG, Heij LR, van Elmpt W, Berbée M, Buijsen J, Lambin P, Sosef MN, Grabsch HI. Lymph node response to chemoradiotherapy in oesophageal cancer patients: relationship with radiotherapy fields. Esophagus 2021;18:100-10. [PMID: 32889674 DOI: 10.1007/s10388-020-00777-y] [Reference Citation Analysis]
107 Zhao Y, Wang Y, Shan L, Peng C, Zhang W, Zhao X. A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus. Sci Rep 2021;11:6800. [PMID: 33762694 DOI: 10.1038/s41598-021-86102-8] [Reference Citation Analysis]
108 Visser E, Franken IA, Brosens LA, Ruurda JP, van Hillegersberg R. Prognostic gene expression profiling in esophageal cancer: a systematic review.Oncotarget. 2017;8:5566-5577. [PMID: 27852047 DOI: 10.18632/oncotarget.13328] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
109 Petrelli F, Ghidini M, Barni S, Sgroi G, Passalacqua R, Tomasello G. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. Gastric Cancer. 2019;22:245-254. [PMID: 30483986 DOI: 10.1007/s10120-018-0901-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
110 Hewitt LC, Inam IZ, Saito Y, Yoshikawa T, Quaas A, Hoelscher A, Bollschweiler E, Fazzi GE, Melotte V, Langley RE, Nankivell M, Cunningham D, Allum W, Hutchins GG, Grabsch HI. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. Eur J Cancer 2018;94:104-14. [PMID: 29550565 DOI: 10.1016/j.ejca.2018.02.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
111 Gronnier C, Collet D. New Trends in Esophageal Cancer Management. Cancers (Basel) 2021;13:3030. [PMID: 34204314 DOI: 10.3390/cancers13123030] [Reference Citation Analysis]
112 Seesing MFJ, van der Veen A, Brenkman HJF, Stockmann HBAC, Nieuwenhuijzen GAP, Rosman C, van den Wildenberg FJH, van Berge Henegouwen MI, van Duijvendijk P, Wijnhoven BPL, Stoot JHMB, Lacle M, Ruurda JP, van Hillegersberg R; Gastroesophageal Metastasectomy Group. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus 2019;32:doz034. [PMID: 31220859 DOI: 10.1093/dote/doz034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
113 Sudo N, Ichikawa H, Muneoka Y, Hanyu T, Kano Y, Ishikawa T, Hirose Y, Miura K, Shimada Y, Nagahashi M, Sakata J, Kobayashi T, Bamba T, Nakagawa S, Kosugi SI, Wakai T. Clinical Utility of ypTNM Stage Grouping in the 8th Edition of the American Joint Committee on Cancer TNM Staging System for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2021;28:650-60. [PMID: 33025354 DOI: 10.1245/s10434-020-09181-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
114 Rice TW, Ishwaran H, Kelsen DP, Hofstetter WL, Apperson-Hansen C, Blackstone EH; Worldwide Esophageal Cancer Collaboration Investigators. Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29:906-912. [PMID: 27905170 DOI: 10.1111/dote.12538] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
115 Huang J, Koulaouzidis A, Marlicz W, Lok V, Chu C, Ngai CH, Zhang L, Chen P, Wang S, Yuan J, Lao XQ, Tse SLA, Xu W, Zheng ZJ, Xie SH, Wong MCS. Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries. Cancers (Basel) 2021;13:E141. [PMID: 33466239 DOI: 10.3390/cancers13010141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
116 Lakenman P, Ottens-Oussoren K, Witvliet-van Nierop J, van der Peet D, de van der Schueren M. Handgrip Strength Is Associated With Treatment Modifications During Neoadjuvant Chemoradiation in Patients With Esophageal Cancer. Nutr Clin Pract 2017;32:652-7. [PMID: 28459652 DOI: 10.1177/0884533617700862] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
117 Miyawaki Y, Sato H, Oya S, Sugita H, Hirano Y, Sakuramoto S, Okamotom K, Yamaguchim S, Koyama I. Clinical impact of abdominal versus mediastinal metastases as a prognostic factor for poor outcomes following esophageal cancer surgery: a retrospective study. BMC Cancer 2021;21:725. [PMID: 34162359 DOI: 10.1186/s12885-021-08484-2] [Reference Citation Analysis]
118 Xu Y, Wang L, He B, Li W, Wen Q, Wang S, Sun X, Meng X, Yu J. Development and validation of a risk prediction model for radiotherapy-related esophageal fistula in esophageal cancer. Radiat Oncol 2019;14:181. [PMID: 31640802 DOI: 10.1186/s13014-019-1385-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
119 Vošmik M, Laco J, Sirák I, Dvořák J, Lochman P, Hodek M, Malá P, Rejchrt S, Repák R, Leško M, Ferko A, Ryška A, Melichar B, Petera J. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery. Pathol Oncol Res 2018;24:373-83. [PMID: 28550507 DOI: 10.1007/s12253-017-0253-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
120 Nowee ME, Voncken FEM, Kotte ANTJ, Goense L, van Rossum PSN, van Lier ALHMW, Heijmink SW, Aleman BMP, Nijkamp J, Meijer GJ, Lips IM; Dutch National Platform for Radiotherapy of Gastrointestinal Tumours (LPRGE) group. Gross tumour delineation on computed tomography and positron emission tomography-computed tomography in oesophageal cancer: A nationwide study. Clin Transl Radiat Oncol 2019;14:33-9. [PMID: 30519647 DOI: 10.1016/j.ctro.2018.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
121 van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. Dig Surg 2019;36:462-9. [PMID: 30227434 DOI: 10.1159/000493435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
122 Kosovec JE, Zaidi AH, Pounardjian TS, Jobe BA. The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy. Front Oncol 2018;8:610. [PMID: 30619750 DOI: 10.3389/fonc.2018.00610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
123 Vadhwana B, Zosimas D, Lykoudis PM, Phen HM, Martinou M, Amalesh T, Khoo D. Adjuvant radiotherapy in oesophageal cancer with positive circumferential resection margins-recurrence and survival outcomes. J Gastrointest Oncol 2019;10:483-91. [PMID: 31183198 DOI: 10.21037/jgo.2019.01.26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Biebl M, Andreou A, Chopra S, Denecke C, Pratschke J. Upper Gastrointestinal Surgery: Robotic Surgery versus Laparoscopic Procedures for Esophageal Malignancy. Visc Med 2018;34:10-5. [PMID: 29594164 DOI: 10.1159/000487011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
125 Yan MH, Hou XB, Cai BN, Qu BL, Dai XK, Liu F. Neoadjuvant chemoradiotherapy plus surgery in the treatment of potentially resectable thoracic esophageal squamous cell carcinoma. World J Clin Cases 2020;8:6315-21. [PMID: 33392312 DOI: 10.12998/wjcc.v8.i24.6315] [Reference Citation Analysis]
126 van Rijswijk AS, Hagens ERC, van der Peet DL, van Berge Henegouwen MI, Gisbertz SS. Differences in Esophageal Cancer Surgery in Terms of Surgical Approach and Extent of Lymphadenectomy: Findings of an International Survey. Ann Surg Oncol 2019;26:2063-72. [PMID: 30903323 DOI: 10.1245/s10434-019-07316-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
127 Urabe M, Yamashita H, Watanabe T, Seto Y. Comparison of Prognostic Abilities Among Preoperative Laboratory Data Indices in Patients with Resectable Gastric and Esophagogastric Junction Adenocarcinoma. World J Surg 2018;42:185-94. [PMID: 28741195 DOI: 10.1007/s00268-017-4146-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
128 Chu Y, Liao J, Li J, Wang Y, Yu X, Wang J, Xu X, Xu L, Zheng L, Xu J, Li L. CD103+ tumor-infiltrating lymphocytes predict favorable prognosis in patients with esophageal squamous cell carcinoma. J Cancer 2019;10:5234-43. [PMID: 31602274 DOI: 10.7150/jca.30354] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
129 Zhou C, Fan N, Liu F, Fang N, Plum PS, Thieme R, Gockel I, Gromnitza S, Hillmer AM, Chon SH, Schlösser HA, Bruns CJ, Zhao Y. Linking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer. Cells 2020;9:E1481. [PMID: 32560537 DOI: 10.3390/cells9061481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
130 Busweiler LAD, Jeremiasen M, Wijnhoven BPL, Lindblad M, Lundell L, van de Velde CJH, Tollenaar RAEM, Wouters MWJM, van Sandick JW, Johansson J, Dikken JL. International benchmarking in oesophageal and gastric cancer surgery. BJS Open 2019;3:62-73. [PMID: 30734017 DOI: 10.1002/bjs5.50107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
131 Deng W, Lin SH. Advances in radiotherapy for esophageal cancer. Ann Transl Med 2018;6:79. [PMID: 29666802 DOI: 10.21037/atm.2017.11.28] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
132 Becskeházi E, Korsós MM, Erőss B, Hegyi P, Venglovecz V. OEsophageal Ion Transport Mechanisms and Significance Under Pathological Conditions. Front Physiol 2020;11:855. [PMID: 32765303 DOI: 10.3389/fphys.2020.00855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
133 Münch S, Oechsner M, Combs SE, Habermehl D. DVH- and NTCP-based dosimetric comparison of different longitudinal margins for VMAT-IMRT of esophageal cancer. Radiat Oncol 2017;12:128. [PMID: 28806990 DOI: 10.1186/s13014-017-0871-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
134 Noordzij IC, Curvers WL, Huysentruyt CJ, Nieuwenhuijzen GAP, Creemers GJ, van der Sangen MJC, Schoon EJ. Salvage endoscopic resection in patients with esophageal adenocarcinoma after chemoradiotherapy. Endosc Int Open. 2018;6:E1126-E1129. [PMID: 30211302 DOI: 10.1055/a-0599-6008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
135 Tang F, Tie Y, Tu C, Wei X. Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies. Clin Transl Med 2020;10:199-223. [PMID: 32508035 DOI: 10.1002/ctm2.24] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
136 Fatehi Hassanabad A, Chehade R, Breadner D, Raphael J. Esophageal carcinoma: Towards targeted therapies. Cell Oncol (Dordr) 2020;43:195-209. [PMID: 31848929 DOI: 10.1007/s13402-019-00488-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
137 Stiles BM, Altorki NK. The NeoRes trial: questioning the benefit of radiation therapy as part of neoadjuvant therapy for esophageal adenocarcinoma. J Thorac Dis 2017;9:3465-8. [PMID: 29268317 DOI: 10.21037/jtd.2017.08.146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Elliott JA, Reynolds JV. Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma. Front Oncol 2021;11:627270. [PMID: 33777773 DOI: 10.3389/fonc.2021.627270] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Zhang Q, Guan F, Fan T, Li S, Ma S, Zhang Y, Guo W, Liu H. LncRNA WDFY3-AS2 suppresses proliferation and invasion in oesophageal squamous cell carcinoma by regulating miR-2355-5p/SOCS2 axis. J Cell Mol Med 2020;24:8206-20. [PMID: 32536038 DOI: 10.1111/jcmm.15488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
140 Anderegg MCJ, van der Sluis PC, Ruurda JP, Gisbertz SS, Hulshof MCCM, van Vulpen M, Mohammed NH, van Laarhoven HWM, Wiezer MJ, Los M, van Berge Henegouwen MI, van Hillegersberg R. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg Oncol. 2017;24:2282-2290. [PMID: 28424936 DOI: 10.1245/s10434-017-5827-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
141 Jiang D, Wang H, Song Q, Wang H, Wang Q, Tan L, Hou Y. Comparison of the prognostic difference between ypTNM and equivalent pTNM stages in esophageal squamous cell carcinoma based on the 8th edition of AJCC classification. J Cancer 2020;11:1808-15. [PMID: 32194792 DOI: 10.7150/jca.34567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Zhang L. PERFECT trial results: Combining neoadjuvant chemoradiotherapy with atezolizumab is feasible in resectable esophageal adenocarcinoma. Thorac Cancer 2021;12:1797-9. [PMID: 33973394 DOI: 10.1111/1759-7714.13972] [Reference Citation Analysis]
143 Vermeulen BD, Siersema PD. Esophageal Stenting in Clinical Practice: an Overview. Curr Treat Options Gastroenterol. 2018;16:260-273. [PMID: 29557070 DOI: 10.1007/s11938-018-0181-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 10.7] [Reference Citation Analysis]
144 Hudson J, Semenkovich T, Puri V. Oncologic Quality Indicators in Thoracic Surgery. Thorac Surg Clin 2017;27:227-44. [PMID: 28647069 DOI: 10.1016/j.thorsurg.2017.04.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
145 Chen Y, Wu X, Hao D, Cheng X, Zhang L, Zhang Y, Ke S, Shi W, He C. Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma. Oncotarget 2019;10:4069-78. [PMID: 31258850 DOI: 10.18632/oncotarget.23861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
146 Yuan M, Bao Y, Ma Z, Men Y, Wang Y, Hui Z. The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients. Front Oncol 2021;11:628706. [PMID: 33777777 DOI: 10.3389/fonc.2021.628706] [Reference Citation Analysis]
147 Chin AL, Aggarwal S, Pradhan P, Bush K, von Eyben R, Koong AC, Chang DT. The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer. Adv Radiat Oncol 2018;3:297-304. [PMID: 30202799 DOI: 10.1016/j.adro.2018.02.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
148 Gaur P, Hunt CR, Pandita TK. Emerging therapeutic targets in esophageal adenocarcinoma. Oncotarget 2016;7:48644-55. [PMID: 27102294 DOI: 10.18632/oncotarget.8777] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
149 Matsumoto Y, Kimura K, Zhou Q, Sasaki K, Saiki T, Moriyama M, Saijo Y. Treatments and outcomes of older patients with esophageal cancer: Comparison with younger patients. Mol Clin Oncol. 2019;11:383-389. [PMID: 31475066 DOI: 10.3892/mco.2019.1909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Jiao R, Zheng X, Sun Y, Feng Z, Song S, Ge H. IDO1 Expression Increased After Neoadjuvant Therapy Predicts Poor Pathologic Response and Prognosis in Esophageal Squamous Cell Carcinoma. Front Oncol 2020;10:1099. [PMID: 32733806 DOI: 10.3389/fonc.2020.01099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
151 Vošmik M, Hodek M, Buka D, Sýkorová P, Grepl J, Paluska P, Paulíková S, Sirák I. Cardiotoxicity of radiation therapy in esophageal cancer. Rep Pract Oncol Radiother 2020;25:318-22. [PMID: 32194352 DOI: 10.1016/j.rpor.2020.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
152 Wang C, Tong J, Tang M, Lu Y, Liang G, Zhang Z, Chen T. Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors and Reference Markers of Treatment Options for Locally Advanced Squamous Cell Carcinoma Located in the Middle and Upper Esophagus. Cancer Manag Res 2021;13:1075-85. [PMID: 33574705 DOI: 10.2147/CMAR.S294344] [Reference Citation Analysis]
153 Guo J, Wang Z, Qin J, Zhang H, Liu W, Zhao Y, Lu Y, Yan X, Zhang Z, Zhang T, Zhang S, Dominik NM, Kamel IR, Li H, Qu J. A prospective analysis of the diagnostic accuracy of 3 T MRI, CT and endoscopic ultrasound for preoperative T staging of potentially resectable esophageal cancer. Cancer Imaging 2020;20:64. [PMID: 32912319 DOI: 10.1186/s40644-020-00343-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Münch S, Habermehl D, Agha A, Belka C, Combs SE, Eckel R, Friess H, Gerbes A, Nüssler NC, Schepp W, Schmid RM, Schmitt W, Schubert-Fritschle G, Weber B, Werner J, Engel J. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. Strahlenther Onkol 2018;194:125-35. [PMID: 29071366 DOI: 10.1007/s00066-017-1225-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
155 Wang HH, de Heer EC, Hulshoff JB, Kats-Ugurlu G, Burgerhof JGM, van Etten B, Plukker JTM, Hospers GAP; Dutch Upper Gastrointestinal Cancer Audit (DUCA) Group. Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis. Ann Surg Oncol 2021;28:3951-60. [PMID: 33249520 DOI: 10.1245/s10434-020-09372-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
156 Chen CY, Li CC, Chien CR. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients. World J Surg Oncol 2018;16:141. [PMID: 30007409 DOI: 10.1186/s12957-018-1444-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
157 Cellini F, Arcelli A, Simoni N, Caravatta L, Buwenge M, Calabrese A, Brunetti O, Genovesi D, Mazzarotto R, Deodato F, Mattiucci GC, Silvestris N, Valentini V, Morganti AG. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers (Basel). 2020;12. [PMID: 32610592 DOI: 10.3390/cancers12071729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
158 Eyck BM, van der Wilk BJ, Noordman BJ, Wijnhoven BPL, Lagarde SM, Hartgrink HH, Coene PPLO, Dekker JWT, Doukas M, van der Gaast A, Heisterkamp J, Kouwenhoven EA, Nieuwenhuijzen GAP, Pierie JEN, Rosman C, van Sandick JW, van der Sangen MJC, Sosef MN, van der Zaag ES, Spaander MCW, Valkema R, Lingsma HF, Steyerberg EW, van Lanschot JJB; SANO-study group. Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer. Trials 2021;22:345. [PMID: 34001287 DOI: 10.1186/s13063-021-05274-w] [Reference Citation Analysis]
159 Zhao Y, Wang N, Zhang X, Liu H, Yang S. LncRNA ZEB1-AS1 down-regulation suppresses the proliferation and invasion by inhibiting ZEB1 expression in oesophageal squamous cell carcinoma. J Cell Mol Med 2019;23:8206-18. [PMID: 31638344 DOI: 10.1111/jcmm.14692] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
160 Depypere LP, Vervloet G, Lerut T, Moons J, De Hertogh G, Sagaert X, Coosemans W, Van Veer H, Nafteux PR. ypT0N+: the unusual patient with pathological complete tumor response but with residual lymph node disease after neoadjuvant chemoradiation for esophageal cancer, what's up? J Thorac Dis 2018;10:2771-8. [PMID: 29997939 DOI: 10.21037/jtd.2018.04.136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
161 Münch S, Pigorsch SU, Feith M, Slotta-Huspenina J, Weichert W, Friess H, Combs SE, Habermehl D. Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Radiat Oncol 2017;12:182. [PMID: 29157271 DOI: 10.1186/s13014-017-0904-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
162 Dai KY, Yu YC, Leu YS, Chi CW, Chan ML, Tsai CH, Lin HC, Huang WC, Chen YJ. Neoadjuvant Chemoradiotherapy and Larynx-Preserving Surgery for Cervical Esophageal Cancer. J Clin Med 2020;9:E387. [PMID: 32024132 DOI: 10.3390/jcm9020387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Ji KSY, Thomas SM, Roman SA, Czito B, Anderson KL Jr, Frakes J, Adam MA, Sosa JA, Robinson TJ. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. J Gastrointest Surg. 2019;23:885-894. [PMID: 30374818 DOI: 10.1007/s11605-018-4007-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
164 Wang Y, Ye D, Kang M, Zhu L, Yang M, Jiang J, Xia W, Kang N, Chen X, Wang J, Wang F. Mapping of Cervical and Upper Mediastinal Lymph Node Recurrence for Guiding Clinical Target Delineation of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma. Front Oncol 2021;11:663679. [PMID: 33981612 DOI: 10.3389/fonc.2021.663679] [Reference Citation Analysis]
165 Donohoe CL, Reynolds JV. Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. J Thorac Dis 2017;9:S697-704. [PMID: 28815065 DOI: 10.21037/jtd.2017.03.159] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
166 Wu SX, Li XY, Xu HY, Xu QN, Luo HS, Du ZS, Huang HC, Wu ZY. Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer. Sci Rep 2017;7:16870. [PMID: 29203855 DOI: 10.1038/s41598-017-17254-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
167 Findlay JM, Dickson E, Fiorani C, Bradley KM, Mukherjee S, Gillies RS, Maynard ND, Middleton MR. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence. Eur Radiol 2019;29:6717-27. [PMID: 31278574 DOI: 10.1007/s00330-019-06310-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
168 Tsukada Y, Higashi T, Shimada H, Kikuchi Y, Terahara A. The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated cancer care hospitals in Japan. Int J Clin Oncol 2018;23:81-91. [PMID: 28795280 DOI: 10.1007/s10147-017-1178-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
169 Lin M, Shen Y, Feng M, Tan L. Minimally invasive esophagectomy: Chinese experiences. J Vis Surg 2016;2:134. [PMID: 29078521 DOI: 10.21037/jovs.2016.07.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
170 Fang P, Shiraishi Y, Verma V, Jiang W, Song J, Hobbs BP, Lin SH. Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation. Int J Part Ther 2018;4:23-32. [PMID: 30079369 DOI: 10.14338/IJPT-17-00033.1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
171 Mukherjee S, Hurt C, Radhakrishna G, Gwynne S, Bateman A, Gollins S, Hawkins MA, Canham J, Grabsch HI, Falk S, Sharma RA, Ray R, Roy R, Cox C, Maynard N, Nixon L, Sebag-Montefiore DJ, Maughan T, Griffiths GO, Crosby TDL. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. Eur J Cancer 2021;153:153-61. [PMID: 34157617 DOI: 10.1016/j.ejca.2021.05.020] [Reference Citation Analysis]
172 Giacopuzzi S, Bencivenga M, Weindelmayer J, Verlato G, de Manzoni G. Western strategy for EGJ carcinoma. Gastric Cancer. 2017;20:60-68. [PMID: 28039533 DOI: 10.1007/s10120-016-0685-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
173 van der Wilk BJ, Eyck BM, Lagarde SM, van der Gaast A, Nuyttens JJME, Wijnhoven BPL, van Lanschot JJB. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis 2019;11:S621-31. [PMID: 31080638 DOI: 10.21037/jtd.2018.11.143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
174 He W, Leng X, Wang K, Mao T, Peng L, Fang Q, Xiao W, Han Y. Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol 2020;11:1105-12. [PMID: 33456985 DOI: 10.21037/jgo-20-504] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Grillo F, Mastracci L, Saragoni L, Vanoli A, Limarzi F, Gullo I, Ferro J, Paudice M, Parente P, Fassan M. Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction. Pathologica 2020;112:138-52. [PMID: 33179618 DOI: 10.32074/1591-951X-164] [Reference Citation Analysis]
176 Matzenauer M, Vrána D, Vlachová Z, Aujesky R, Vrba R, Neoral C, Melichar B. Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer. Oncol Lett 2017;13:1807-10. [PMID: 28454327 DOI: 10.3892/ol.2017.5605] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
177 Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J; AME Thoracic Surgery Collaborative Group. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018;36:2796-2803. [PMID: 30089078 DOI: 10.1200/jco.2018.79.1483] [Cited by in Crossref: 142] [Cited by in F6Publishing: 92] [Article Influence: 47.3] [Reference Citation Analysis]
178 Xu C, Jin JY, Zhang M, Liu A, Wang J, Mohan R, Kong FS, Lin SH. The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol 2020;146:180-6. [PMID: 32182504 DOI: 10.1016/j.radonc.2020.02.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
179 Lim SH, Shim YM, Park SH, Kim HK, Choi YS, Ahn MJ, Park K, Zo JI, Sun JM. A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma. Cancer Res Treat 2017;49:816-23. [PMID: 27857024 DOI: 10.4143/crt.2016.417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
180 Innocente R, Navarria F, Petri R, Palazzari E, Vecchiato M, Polesel J, Ziccarelli A, Martino A, Ubiali P, Tonin D, Lauretta A, Belluco C, Foltran L, Buonadonna A, Lleshi A, Colombo CB, Barresi L, Gigante M, Franchin G, De Paoli A. Feasibility and Oncological Outcome of Preoperative Chemoradiation With IMRT Dose Intensification for Locally Advanced Esophageal and Gastroesophageal Cancer. Front Oncol 2021;11:626275. [PMID: 33680967 DOI: 10.3389/fonc.2021.626275] [Reference Citation Analysis]
181 Goense L, Ruurda JP, Carter BW, Fang P, Ho L, Meijer GJ, van Hillegersberg R, Hofstetter WL, Lin SH. Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2018;45:1742-51. [PMID: 29663014 DOI: 10.1007/s00259-018-4011-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
182 Fermin L, Arnold S, Nunez L, Yakoub D. Extracorporeal membrane oxygenation for repair of tracheal injury during transhiatal esophagectomy. Ann Card Anaesth 2017;20:S67-9. [PMID: 28074826 DOI: 10.4103/0971-9784.197803] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
183 van Vulpen JK, Siersema PD, van Hillegersberg R, Nieuwenhuijzen GAP, Kouwenhoven EA, Groenendijk RPR, van der Peet DL, Hazebroek EJ, Rosman C, Schippers CCG, Steenhagen E, Peeters PHM, May AM. Physical ExeRcise Following Esophageal Cancer Treatment (PERFECT) study: design of a randomized controlled trial. BMC Cancer 2017;17:552. [PMID: 28821284 DOI: 10.1186/s12885-017-3542-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
184 Frede J, Greulich P, Nagy T, Simons BD, Jones PH. A single dividing cell population with imbalanced fate drives oesophageal tumour growth. Nat Cell Biol 2016;18:967-78. [PMID: 27548914 DOI: 10.1038/ncb3400] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
185 Xia Y, Li YH, Chen Y, Liu Q, Zhang JH, Deng JY, Ai TS, Zhu HT, Badakhshi H, Zhao KL. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma. Int J Clin Oncol 2018;23:458-65. [PMID: 29435872 DOI: 10.1007/s10147-018-1240-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
186 Hoang AT, Vizio B, Chiusa L, Cimino A, Solerio D, Do NH, Pileci S, Camandona M, Bellone G. Impact of Tissue Enolase 1 Protein Overexpression in Esophageal Cancer Progression. Int J Med Sci 2021;18:1406-14. [PMID: 33628097 DOI: 10.7150/ijms.52688] [Reference Citation Analysis]
187 Faiz Z, van Putten M, Verhoeven RHA, van Sandick JW, Nieuwenhuijzen GAP, van der Sangen MJC, Lemmens VEPP, Wijnhoven BPL, Plukker JTM. Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer. Ann Surg Oncol 2019;26:986-95. [PMID: 30719634 DOI: 10.1245/s10434-019-07181-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
188 Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg 2018;2:253-65. [PMID: 30003188 DOI: 10.1002/ags3.12174] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
189 Luo A, Zhou X, Shi X, Zhao Y, Men Y, Chang X, Chen H, Ding F, Li Y, Su D, Xiao Z, Hui Z, Liu Z. Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma. Oncogene 2019;38:4990-5006. [PMID: 30858545 DOI: 10.1038/s41388-019-0771-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
190 Markar SR, Noordman BJ, Mackenzie H, Findlay JM, Boshier PR, Ni M, Steyerberg EW, van der Gaast A, Hulshof MCCM, Maynard N, van Berge Henegouwen MI, Wijnhoven BPL, Reynolds JV, Van Lanschot JJB, Hanna GB. Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study. Ann Oncol 2017;28:519-27. [PMID: 28039180 DOI: 10.1093/annonc/mdw560] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
191 Dröge LH, Karras PJ, Guhlich M, Schirmer MA, Ghadimi M, Rieken S, Conradi LC, Leu M. Preoperative Radiochemotherapy in Esophageal Squamous Cell Cancer with 5-Fluorouracil/Cisplatin or Carboplatin/Paclitaxel: Treatment Practice over a 20-Year Period and Implications for the Individual Treatment Modalities. Cancers (Basel) 2021;13:1834. [PMID: 33921384 DOI: 10.3390/cancers13081834] [Reference Citation Analysis]
192 Cuesta MA, van der Peet DL, Gisbertz SS, Straatman J. Mediastinal lymphadenectomy for esophageal cancer: Differences between two countries, Japan and the Netherlands. Ann Gastroenterol Surg 2018;2:176-81. [PMID: 29863178 DOI: 10.1002/ags3.12172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
193 Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers (Basel) 2021;13:582. [PMID: 33540736 DOI: 10.3390/cancers13030582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
194 Zhang C, Zhang Z, Zhang G, Xue L, Yang H, Luo Y, Zheng X, Zhang Y, Yuan Y, Lei R, Yang Z, Zheng B, Zhang Z, Wang L, Che Y, Wang S, Wang F, Fang L, Zeng Q, Li J, Gao S, Xue Q, Sun N, He J. A three-lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy. Clin Transl Med 2020;10:e156. [PMID: 32898328 DOI: 10.1002/ctm2.156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
195 Wu SG, Xie WH, Zhang ZQ, Sun JY, Li FY, Lin HX, Yong Bao, He ZY. Surgery Combined with Radiotherapy Improved Survival in Metastatic Esophageal Cancer in a Surveillance Epidemiology and End Results Population-based Study. Sci Rep 2016;6:28280. [PMID: 27323696 DOI: 10.1038/srep28280] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
196 Kalff MC, Wagner AD, Verhoeven RHA, Lemmens VEPP, van Laarhoven HWM, Gisbertz SS, van Berge Henegouwen MI; Dutch Upper GI Cancer Audit group. Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. Gastric Cancer 2021. [PMID: 34365540 DOI: 10.1007/s10120-021-01225-1] [Reference Citation Analysis]
197 Defize IL, van Hillegersberg R, Mook S, Meijer GJ, Lin SH, Ruurda JP, van Rossum PSN. Restaging after chemoradiotherapy for locally advanced esophageal cancer. Ann Transl Med 2019;7:S288. [PMID: 32016007 DOI: 10.21037/atm.2019.11.57] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
198 Rasmussen SR, Nielsen RV, Fenger AS, Siemsen M, Ravn HB. Postoperative complications and survival after surgical resection of esophageal squamous cell carcinoma. J Thorac Dis 2018;10:4052-60. [PMID: 30174848 DOI: 10.21037/jtd.2018.07.04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
199 Ristau J, Thiel M, Katayama S, Schlampp I, Lang K, Häfner MF, Herfarth K, Debus J, Koerber SA. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity. Radiat Oncol 2021;16:23. [PMID: 33522923 DOI: 10.1186/s13014-021-01749-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
200 Riechelmann RP, Peixoto RD, Fernandes GDS, Weschenfelder RF, Prolla G, Filho DR, Andrade AC, Crosara M, Rego JFM, Gansl RC, Coimbra F, Aguiar S Jr, Carvalho E, Hoff PM, Coutinho AK. Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. Ecancermedicalscience 2020;14:1048. [PMID: 32565901 DOI: 10.3332/ecancer.2020.1048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
201 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Reference Citation Analysis]
202 Melsens E, De Vlieghere E, Descamps B, Vanhove C, Kersemans K, De Vos F, Goethals I, Brans B, De Wever O, Ceelen W, Pattyn P. Hypoxia imaging with 18F-FAZA PET/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts. Radiat Oncol 2018;13:39. [PMID: 29514673 DOI: 10.1186/s13014-018-0984-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
203 Li C, Lin JW, Yeh HL, Chuang CY, Chen CC. Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism. Sci Rep 2021;11:11626. [PMID: 34078965 DOI: 10.1038/s41598-021-90753-y] [Reference Citation Analysis]
204 Liu G, Han Y, Peng L, Wang K, Fan Y. Reliability and safety of minimally invasive esophagectomy after neoadjuvant chemoradiation: a retrospective study. J Cardiothorac Surg 2019;14:97. [PMID: 31138245 DOI: 10.1186/s13019-019-0920-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
205 Zhang C, Zhang G, Sun N, Zhang Z, Xue L, Zhang Z, Yang H, Luo Y, Zheng X, Zhang Y, Yuan Y, Lei R, Yang Z, Zheng B, Wang L, Che Y, Wang F, Wang S, Gao S, Xue Q, Zhang Y, He J. An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma. Signal Transduct Target Ther 2020;5:182. [PMID: 32883946 DOI: 10.1038/s41392-020-00221-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
206 Allen S, Brown V, Prabhu P, Scott M, Rockall T, Preston S, Sultan J. A randomised controlled trial to assess whether prehabilitation improves fitness in patients undergoing neoadjuvant treatment prior to oesophagogastric cancer surgery: study protocol. BMJ Open 2018;8:e023190. [PMID: 30580268 DOI: 10.1136/bmjopen-2018-023190] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
207 Tang H, Tan L, Shen Y, Wang H, Lin M, Feng M, Xu S, Guo W, Qian C, Liu T, Zeng Z, Hou Y, Yu Z, Jiang H, Li Z, Chen C, Lian C, Du M, Li H, Xie D, Yin J, Zhao N, Wang Q. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0) (NCT03001596). BMC Cancer 2017;17:450. [PMID: 28659128 DOI: 10.1186/s12885-017-3446-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
208 Li S, Liu H, Diao C, Wang X, Gao M, Li Z, Song L, Gao X, Han J, Wang F, Li W, Han X. Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis. Oncotarget 2017;8:36339-53. [PMID: 28423740 DOI: 10.18632/oncotarget.16193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
209 Ji A, Jin R, Zhang R, Li H. Primary small cell carcinoma of the esophagus: progression in the last decade. Ann Transl Med 2020;8:502. [PMID: 32395546 DOI: 10.21037/atm.2020.03.214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Kumaran D, John S, Isiah R, Das S. Management of Locally Advanced Carcinoma Oesophagus with Radiation/Chemoradiation: Single Institute Experience. J Gastrointest Cancer 2016;47:313-7. [PMID: 27146042 DOI: 10.1007/s12029-016-9825-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
211 Xu C, Guo L, Liao Z, Wang Y, Liu X, Zhao S, Wang J, Yuan Z, Wang P, Lin SH. Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. Clin Transl Radiat Oncol 2019;17:17-23. [PMID: 31080898 DOI: 10.1016/j.ctro.2019.04.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
212 Depypere L, Coosemans W, Nafteux P, Van Veer H, Neyrinck A, Coppens S, Boelens C, Laes K, Lerut T. Video-assisted thoracoscopic surgery and open chest surgery in esophageal cancer treatment: present and future. J Vis Surg 2017;3:30. [PMID: 29078593 DOI: 10.21037/jovs.2017.01.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
213 Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RGP, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON)., Esophageal Adenocarcinoma GenEtics Consortium (EAGLE)., Wellcome Trust Case Control Consortium 2 (WTCCC2). Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncol 2016;17:1363-73. [PMID: 27527254 DOI: 10.1016/S1470-2045(16)30240-6] [Cited by in Crossref: 83] [Cited by in F6Publishing: 37] [Article Influence: 16.6] [Reference Citation Analysis]
214 Nakayama I, Takahari D, Wakatsuki T, Osumi H, Chin K, Ogura M, Sato T, Suzuki T, Kamiimabeppu D, Ooki A, Suenaga M, Shinozaki E, Yamaguchi K. Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting. ESMO Open 2020;5:e000595. [PMID: 32273288 DOI: 10.1136/esmoopen-2019-000595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Goedegebuure RSA, Harrasser M, de Klerk LK, van Schooten TS, van Grieken NCT, Eken M, Grifhorst MS, Pocorni N, Jordanova ES, van Berge Henegouwen MI, Pouw RE, Verheul HMW, van der Vliet JJ, van Laarhoven HWM, Thijssen VLJL, Bass AJ, De Gruijl TD, Derks S. Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma. Oncoimmunology 2021;10:1954807. [PMID: 34377591 DOI: 10.1080/2162402X.2021.1954807] [Reference Citation Analysis]
216 Meijer LL, Alberga AJ, de Bakker JK, van der Vliet HJ, Le Large TYS, van Grieken NCT, de Vries R, Daams F, Zonderhuis BM, Kazemier G. Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2018;25:2681-2692. [PMID: 29946997 DOI: 10.1245/s10434-018-6567-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 6.7] [Reference Citation Analysis]
217 Slotta-Huspenina J, Drecoll E, Feith M, Habermehl D, Combs S, Weichert W, Bettstetter M, Becker K, Langer R. MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus. J Transl Med. 2018;16:109. [PMID: 29695253 DOI: 10.1186/s12967-018-1492-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
218 Abbas G, Krasna M. Overview of esophageal cancer. Ann Cardiothorac Surg. 2017;6:131-136. [PMID: 28447001 DOI: 10.21037/acs.2017.03.03] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 14.0] [Reference Citation Analysis]
219 Cheng CY, Liu CJ, Huang YC, Wu SH, Fang HW, Chen YJ. BI2536 induces mitotic catastrophe and radiosensitization in human oral cancer cells. Oncotarget 2018;9:21231-43. [PMID: 29765534 DOI: 10.18632/oncotarget.25035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
220 Linder G, Klevebro F, Edholm D, Johansson J, Lindblad M, Hedberg J. Burden of in-hospital care in oesophageal cancer: national population-based study. BJS Open 2021;5:zrab037. [PMID: 33960365 DOI: 10.1093/bjsopen/zrab037] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Hollertz P, Lindblad M, Sandström P, Halldestam I, Edholm D. Outcome of microscopically non-radical oesophagectomy for oesophageal and oesophagogastric junctional cancer: nationwide cohort study. BJS Open 2021;5:zrab038. [PMID: 33972990 DOI: 10.1093/bjsopen/zrab038] [Reference Citation Analysis]
222 Anderluh F, Toplak M, Velenik V, Oblak I, Ermenc AS, Peressutti AJ, But-Hadzic J, Vidmar MS. Definitive radiochemotherapy in esophageal cancer - a single institution experience. Radiol Oncol 2019;53:480-7. [PMID: 31747382 DOI: 10.2478/raon-2019-0054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
223 Heinrich S, Besselink M, Moehler M, van Laethem JL, Ducreux M, Grimminger P, Mittler J, Lang H, Lutz MP, Lesurtel M;  Scientific and Research Committee of the E-AHPBA and the EORTC pancreas working group. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. BMC Cancer. 2019;19:675. [PMID: 31288786 DOI: 10.1186/s12885-019-5889-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
224 Lopes N, Correia MP, Henrique R, Jerónimo C. Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes. Int J Mol Sci 2020;21:E3522. [PMID: 32429269 DOI: 10.3390/ijms21103522] [Reference Citation Analysis]
225 Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020;10:245. [PMID: 32185128 DOI: 10.3389/fonc.2020.00245] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 29.0] [Reference Citation Analysis]
226 Wu Z, Zheng Q, Chen H, Xiang J, Hu H, Li H, Pan Y, Peng Y, Yao X, Liu P, Sun Y, Li B, Zhang Y. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. J Thorac Dis 2021;13:3518-28. [PMID: 34277047 DOI: 10.21037/jtd-21-340] [Reference Citation Analysis]
227 Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F, Lieto E, Galizia G, Castoro C, De Vita F. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers (Basel) 2019;11:E399. [PMID: 30901943 DOI: 10.3390/cancers11030399] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
228 Ebbing EA, van der Zalm AP, Steins A, Creemers A, Hermsen S, Rentenaar R, Klein M, Waasdorp C, Hooijer GKJ, Meijer SL, Krishnadath KK, Punt CJA, van Berge Henegouwen MI, Gisbertz SS, van Delden OM, Hulshof MCCM, Medema JP, van Laarhoven HWM, Bijlsma MF. Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. Proc Natl Acad Sci U S A 2019;116:2237-42. [PMID: 30670657 DOI: 10.1073/pnas.1820459116] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 24.0] [Reference Citation Analysis]
229 Ma Z, Wu X, Xu B, Jiang H, Tang P, Yue J, Ma M, Chen C, Zhang H, Yu Z. Development of a novel biomarker model for predicting preoperative lymph node metastatic extent in esophageal squamous cell carcinoma1. Oncotarget 2017;8:105790-9. [PMID: 29285292 DOI: 10.18632/oncotarget.22399] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
230 Kingma BF, Eshuis WJ, de Groot EM, Feenstra ML, Ruurda JP, Gisbertz SS, Ten Hoope W, Marsman M, Hermanides J, Hollmann MW, Kalkman CJ, Luyer MDP, Nieuwenhuijzen GAP, Scholten HJ, Buise M, van Det MJ, Kouwenhoven EA, van der Meer F, Frederix GWJ, Cheong E, Al Naimi K, van Berge Henegouwen MI, van Hillegersberg R. Paravertebral catheter versus EPidural analgesia in Minimally invasive Esophageal resectioN: a randomized controlled multicenter trial (PEPMEN trial). BMC Cancer 2020;20:142. [PMID: 32087686 DOI: 10.1186/s12885-020-6585-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
231 Messager M, Mirabel X, Tresch E, Paumier A, Vendrely V, Dahan L, Glehen O, Vasseur F, Lacornerie T, Piessen G, El Hajbi F, Robb WB, Clisant S, Kramar A, Mariette C, Adenis A. Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. BMC Cancer 2016;16:318. [PMID: 27194176 DOI: 10.1186/s12885-016-2335-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
232 Steber C, Hughes RT, McTyre ER, Soike M, Farris M, Levine BJ, Pasche B, Levine E, Blackstock AW. Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer. Cureus 2021;13:e12574. [PMID: 33575139 DOI: 10.7759/cureus.12574] [Reference Citation Analysis]
233 Bolger JC, Donlon NE, Butt W, Neary C, Al Azzawi M, Brett O, King S, Downey E, Arumugasamy M, Murphy T, Robb WB, Collins CG, Carroll PA, Donohoe CL, Ravi N, Reynolds JV. Successful maintenance of process and outcomes for oesophageal cancer surgery in Ireland during the first wave of the COVID-19 pandemic. Ir J Med Sci 2021. [PMID: 33728528 DOI: 10.1007/s11845-021-02597-0] [Reference Citation Analysis]
234 Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH. 18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. J Nucl Med 2017;58:1756-63. [PMID: 28522744 DOI: 10.2967/jnumed.117.192591] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
235 Feng H, Zhao Y, Jing T, Ma J, Zhao Y, Zhang J, Wang C, Li B. Traditional and cumulative meta-analysis: Chemoradiotherapy followed by surgery versus surgery alone for resectable esophageal carcinoma. Mol Clin Oncol 2018;8:342-51. [PMID: 29435301 DOI: 10.3892/mco.2017.1534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
236 Unger K, Li Y, Yeh C, Barac A, Srichai MB, Ballew EA, Girgis M, Jayatilake M, Sridharan V, Boerma M, Cheema AK. Plasma metabolite biomarkers predictive of radiation induced cardiotoxicity. Radiother Oncol 2020;152:133-45. [PMID: 32360032 DOI: 10.1016/j.radonc.2020.04.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
237 Roy A, Gabani P, Davis EJ, Oppelt P, Merfeld E, Keedy VL, Zoberi I, Chrisinger JSA, Michalski JM, Van Tine B, Spraker MB. Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma. Clin Transl Radiat Oncol 2021;27:114-20. [PMID: 33604458 DOI: 10.1016/j.ctro.2021.01.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BC, Bordia S, Bhagia P, Shih CS, Desai A, Enzinger P. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol 2021;17:1143-53. [PMID: 33533655 DOI: 10.2217/fon-2020-0969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
239 Chen D, Mao Y, Xue Y, Sang Y, Liu D, Chen Y. Does the lymph node yield affect survival in patients with esophageal cancer receiving neoadjuvant therapy plus esophagectomy? A systematic review and updated meta-analysis. EClinicalMedicine 2020;25:100431. [PMID: 32775970 DOI: 10.1016/j.eclinm.2020.100431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
240 Ashok A, Tiwari V, Jiwnani S, Karimundackal G, Pramesh CS. Controversies in preoperative therapy in esophageal cancer: Current evidence and ongoing research. Ann Gastroenterol Surg 2019;3:592-7. [PMID: 31788647 DOI: 10.1002/ags3.12301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
241 Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919864850. [PMID: 31384313 DOI: 10.1177/1758835919864850] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
242 Triantafyllou T, Wijnhoven BPL. Current status of esophageal cancer treatment. Chin J Cancer Res 2020;32:271-86. [PMID: 32694894 DOI: 10.21147/j.issn.1000-9604.2020.03.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
243 Keung EZ, Gershenwald JE. Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. J Natl Cancer Inst 2020;112:875-85. [PMID: 32061122 DOI: 10.1093/jnci/djaa012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
244 Matsuda S, Takeuchi H, Kawakubo H, Ando N, Kitagawa Y. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan. Ann Thorac Cardiovasc Surg 2016;22:275-83. [PMID: 27384595 DOI: 10.5761/atcs.ra.16-00111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
245 Creemers A, Ebbing EA, Pelgrim TC, Lagarde SM, van Etten-Jamaludin FS, van Berge Henegouwen MI, Hulshof MCCM, Krishnadath KK, Meijer SL, Bijlsma MF, van Oijen MGH, van Laarhoven HWM. A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas. Sci Rep 2018;8:13281. [PMID: 30185893 DOI: 10.1038/s41598-018-31548-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
246 Wu Y, Li J. Change in Maximal Esophageal Wall Thickness Provides Prediction of Survival and Recurrence in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy and Surgery. Cancer Manag Res 2021;13:2433-45. [PMID: 33758542 DOI: 10.2147/CMAR.S295646] [Reference Citation Analysis]
247 Cummings Iii KC, Kou TD, Chak A, Schluchter MD, Margevicius S, Cooper GS, Meropol NJ, Perry Y, Linden PA, Cummings LC. Surgical approach and the impact of epidural analgesia on survival after esophagectomy for cancer: A population-based retrospective cohort study. PLoS One 2019;14:e0211125. [PMID: 30668599 DOI: 10.1371/journal.pone.0211125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
248 Cai Z, Yin Y, Zhao Z, Xin C, Cai Z, Yin Y, Shen C, Yin X, Wang J, Chen Z, Zhou Y, Zhang B. Comparative effectiveness of neoadjuvant treatments for resectable gastroesophageal cancer: a network meta-analysis. Front Pharmacol. 2018;9:872. [PMID: 30127746 DOI: 10.3389/fphar.2018.00872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
249 Rocha-Filho DR, Peixoto RD, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Di Paula Filho RP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Ribeiro U Jr, Jesus VHF, Costa WL Jr, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021;15:1195. [PMID: 33889204 DOI: 10.3332/ecancer.2021.1195] [Reference Citation Analysis]
250 Shiraishi O, Yasuda T, Kato H, Iwama M, Hiraki Y, Yasuda A, Shinkai M, Kimura Y, Imano M. Risk Factors and Prognostic Impact of Mediastinal Lymph Node Metastases in Patients with Esophagogastric Junction Cancer. Ann Surg Oncol 2020;27:4433-40. [PMID: 32409967 DOI: 10.1245/s10434-020-08579-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
251 Münz F, Lopez Perez R, Trinh T, Sisombath S, Weber KJ, Wuchter P, Debus J, Saffrich R, Huber PE, Nicolay NH. Human mesenchymal stem cells lose their functional properties after paclitaxel treatment. Sci Rep 2018;8:312. [PMID: 29321693 DOI: 10.1038/s41598-017-18862-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
252 Brenkman HJF, van der Wielen NI, Ruurda JP, van Leeuwen MS, Scheepers JJG, van der Peet DL, van Hillegersberg R, Bleys RLAW, Cuesta MA. Surgical anatomy of the omental bursa and the stomach based on a minimally invasive approach: different approaches and technical steps to resection and lymphadenectomy. J Thorac Dis 2017;9:S809-16. [PMID: 28815078 DOI: 10.21037/jtd.2017.07.52] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
253 Glatz T, Höppner J. Is There a Rationale for Structural Quality Assurance in Esophageal Surgery? Visc Med 2017;33:135-9. [PMID: 28560229 DOI: 10.1159/000458454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
254 Conway AM, Salih Z, Papaxoinis G, Fletcher K, Weaver J, Patrao A, Noble R, Stamatopoulou S, Owen-Holt V, Mansoor W. Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging. Med Oncol 2017;34:116. [PMID: 28500616 DOI: 10.1007/s12032-017-0976-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
255 van der Horst S, Weijs TJ, Ruurda JP, Haj Mohammad N, Mook S, Brosens LAA, van Hillegersberg R. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy for esophageal cancer in the upper mediastinum. J Thorac Dis 2017;9:S834-42. [PMID: 28815081 DOI: 10.21037/jtd.2017.03.151] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
256 Tang J, Xu H, Liu Q, Zheng J, Pan C, Li Z, Wen W, Wang J, Zhu Q, Wang Z, Chen L. LncRNA LOC146880 promotes esophageal squamous cell carcinoma progression via miR-328-5p/FSCN1/MAPK axis. Aging (Albany NY) 2021;13:14198-218. [PMID: 34016787 DOI: 10.18632/aging.203037] [Reference Citation Analysis]
257 Cartwright E, Cunningham D. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Curr Treat Options Oncol 2017;18:69. [PMID: 29143893 DOI: 10.1007/s11864-017-0510-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
258 Bonavina L, Asti E, Sironi A, Bernardi D, Aiolfi A. Hybrid and total minimally invasive esophagectomy: how I do it. J Thorac Dis 2017;9:S761-72. [PMID: 28815072 DOI: 10.21037/jtd.2017.06.55] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
259 Scholtemeijer MG, Seesing MFJ, Brenkman HJF, Janssen LM, van Hillegersberg R, Ruurda JP. Recurrent laryngeal nerve injury after esophagectomy for esophageal cancer: incidence, management, and impact on short- and long-term outcomes. J Thorac Dis 2017;9:S868-78. [PMID: 28815085 DOI: 10.21037/jtd.2017.06.92] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
260 Seesing MFJ, Borggreve AS, Ruurda JP, van Hillegersberg R. New-onset atrial fibrillation after esophagectomy for cancer. J Thorac Dis 2019;11:S831-4. [PMID: 31080666 DOI: 10.21037/jtd.2019.02.03] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
261 Helminen O, Mrena J, Sihvo E. Can We Increase the Resection Rate by Minimally Invasive Approach? Experience from 100 Minimally Invasive Esophagectomies. J Oncol 2019;2019:3809383. [PMID: 30915119 DOI: 10.1155/2019/3809383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 Jamel S, Tukanova K, Markar S. Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: A systematic review. World J Gastrointest Oncol 2019;11:741-9. [PMID: 31558978 DOI: 10.4251/wjgo.v11.i9.741] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
263 Feng JF, Wang L, Yang X, Chen S. Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma. J Cancer 2020;11:1334-40. [PMID: 32047540 DOI: 10.7150/jca.37898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
264 McCain RS, McManus DT, McQuaid S, James JA, Salto-Tellez M, Reid NB, Craig S, Chisambo C, Bingham V, McCarron E, Parkes E, Turkington RC, Coleman HG. Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study. Cancer Causes Control 2020;31:1-11. [PMID: 31786674 DOI: 10.1007/s10552-019-01247-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
265 Anandavadivelan P, Wikman A, Mälberg K, Rosenlund H, Johar A, Lagergren P. Role of dietitian support in improving weight loss and nutrition impact symptoms after oesophageal cancer surgery. Eur J Clin Nutr 2021;75:1134-41. [PMID: 33446903 DOI: 10.1038/s41430-020-00830-0] [Reference Citation Analysis]
266 Yu X, Huang M, Yang G. Long non‑coding RNA BANCR promotes proliferation, invasion and migration in esophageal squamous cell carcinoma cells via the Raf/MEK/ERK signaling pathway. Mol Med Rep 2021;23:465. [PMID: 33880577 DOI: 10.3892/mmr.2021.12104] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 van den Ende T, Ter Veer E, Mali RMA, van Berge Henegouwen MI, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E530. [PMID: 31013858 DOI: 10.3390/cancers11040530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
268 Bang A, Broomfield JA, Chan J, Alyamani N, Crnic A, Gilbert S, Pantarotto JR. Radiation dose mapping and anastomotic complications after trimodality therapy for esophageal cancers. Clin Transl Radiat Oncol 2019;15:76-82. [PMID: 30775562 DOI: 10.1016/j.ctro.2018.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
269 Larue RT, Van De Voorde L, Berbée M, van Elmpt WJ, Dubois LJ, Panth KM, Peeters SG, Claessens A, Schreurs WM, Nap M, Warmerdam FA, Erdkamp FL, Sosef MN, Lambin P. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer 2016;16:644. [PMID: 27535748 DOI: 10.1186/s12885-016-2709-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
270 Münch S, Aichmeier S, Hapfelmeier A, Duma MN, Oechsner M, Feith M, Combs SE, Habermehl D. Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT. Strahlenther Onkol 2016;192:722-9. [PMID: 27418129 DOI: 10.1007/s00066-016-1020-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
271 van Pelt GW, Krol JA, Lips IM, Peters FP, van Klaveren D, Boonstra JJ, de Steur WO, Tollenaar RAEM, Farina Sarasqueta A, Mesker WE, Slingerland M. The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer. Clin Transl Radiat Oncol 2020;20:39-44. [PMID: 31886418 DOI: 10.1016/j.ctro.2019.11.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
272 Solomon BL, Garrido-Laguna I. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncol 2018;14:947-62. [PMID: 29542354 DOI: 10.2217/fon-2017-0597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
273 Aquina CT, Ejaz A, Tsung A, Pawlik TM, Cloyd JM. National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016.JAMA Netw Open. 2021;4:e211031. [PMID: 33688961 DOI: 10.1001/jamanetworkopen.2021.1031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
274 Zhang X, Eyck BM, Yang Y, Liu J, Chao YK, Hou MM, Hung TM, Pang Q, Yu ZT, Jiang H, Law S, Wong I, Lam KO, van der Wilk BJ, van der Gaast A, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB, Li Z. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study. BMC Cancer 2020;20:194. [PMID: 32143580 DOI: 10.1186/s12885-020-6669-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
275 Plum PS, Damanakis A, Buschmann L, Ernst A, Datta RR, Schiffmann LM, Zander T, Fuchs H, Chon SH, Alakus H, Schröder W, Hölscher AH, Bruns CJ, Bludau M. Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis. J Cancer Res Clin Oncol 2021. [PMID: 34223965 DOI: 10.1007/s00432-021-03720-5] [Reference Citation Analysis]
276 Reece-Smith AM, Saunders JH, Soomro IN, Bowman CR, Duffy JP, Kaye PV, Welch NT, Madhusudan S, Parsons SL. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma. Ann R Coll Surg Engl 2017;99:378-84. [PMID: 28462649 DOI: 10.1308/rcsann.2017.0024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
277 Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I. Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open 2018;3:e000386. [PMID: 30094072 DOI: 10.1136/esmoopen-2018-000386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
278 Murakami Y, Kawahara D, Tani S, Kubo K, Katsuta T, Imano N, Takeuchi Y, Nishibuchi I, Saito A, Nagata Y. Predicting the Local Response of Esophageal Squamous Cell Carcinoma to Neoadjuvant Chemoradiotherapy by Radiomics with a Machine Learning Method Using 18F-FDG PET Images. Diagnostics (Basel) 2021;11:1049. [PMID: 34200332 DOI: 10.3390/diagnostics11061049] [Reference Citation Analysis]
279 Zhou HY, Zheng SP, Li AL, Gao QL, Ou QY, Chen YJ, Wu ST, Lin DG, Liu SB, Huang LY, Li FS, Zhu HY, Qiao GB, Lanuti M, Yao HR, Yu YF. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study). EClinicalMedicine 2020;24:100422. [PMID: 32637899 DOI: 10.1016/j.eclinm.2020.100422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
280 Liu B, Bo Y, Wang K, Liu Y, Tang X, Zhao Y, Zhao E, Yuan L. Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials. Oncotarget 2017;8:20410-7. [PMID: 28099899 DOI: 10.18632/oncotarget.14669] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
281 Depypere L, Thomas M, Moons J, Coosemans W, Lerut T, Prenen H, Haustermans K, Van Veer H, Nafteux P. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. World J Surg Oncol 2019;17:89. [PMID: 31133018 DOI: 10.1186/s12957-019-1630-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
282 Li Y, Liu J, Li HX, Cai XW, Li ZG, Ye XD, Teng HH, Fu XL, Yu W. Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy. Front Oncol 2020;10:615167. [PMID: 33680935 DOI: 10.3389/fonc.2020.615167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
283 Joseph R, Laks S, Meyers M, McRee AJ. Multidisciplinary Approach to the Management of Esophageal Malignancies. World J Surg 2017;41:1726-33. [PMID: 28361298 DOI: 10.1007/s00268-017-4009-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
284 Gamboa AC, Meyer BI, Switchenko JM, Rupji M, Lee RM, Turgeon MK, Russell MC, Cardona K, Kooby DA, Maithel SK, Shah MM. Should adenosquamous esophageal cancer be treated like adenocarcinoma or squamous cell carcinoma? J Surg Oncol 2020;122:412-21. [PMID: 32462769 DOI: 10.1002/jso.25990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
285 Qiu Z, Jiang H, Ju K, Liu X. A Novel RNA-Binding Protein Signature to Predict Clinical Outcomes and Guide Clinical Therapy in Gastric Cancer. Front Med (Lausanne) 2021;8:670141. [PMID: 34336882 DOI: 10.3389/fmed.2021.670141] [Reference Citation Analysis]
286 van Rossum PSN, Fried DV, Zhang L, Hofstetter WL, Ho L, Meijer GJ, Carter BW, Court LE, Lin SH. The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma. Eur J Nucl Med Mol Imaging 2017;44:71-80. [PMID: 27511188 DOI: 10.1007/s00259-016-3478-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
287 Zhao X, Ren Y, Hu Y, Cui N, Wang X, Cui Y. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials. PLoS One 2018;13:e0202185. [PMID: 30138325 DOI: 10.1371/journal.pone.0202185] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
288 Jezerskyte E, Saadeh LM, Hagens ERC, Sprangers MAG, Noteboom L, van Laarhoven HWM, Eshuis WJ, Hulshof MCCM, van Berge Henegouwen MI, Gisbertz SS. Long-term health-related quality of life after McKeown and Ivor Lewis esophagectomy for esophageal carcinoma. Dis Esophagus 2020;33:doaa022. [PMID: 32444879 DOI: 10.1093/dote/doaa022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
289 Blackham AU, H Naqvi SM, Schell MJ, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. J Surg Oncol 2018;117:150-9. [PMID: 28833197 DOI: 10.1002/jso.24808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
290 Veenstra MMK, Smithers BM, Visser E, Edholm D, Brosda S, Thomas JM, Gotley DC, Thomson IG, Wijnhoven BPL, Barbour AP. Complications and survival after hybrid and fully minimally invasive oesophagectomy. BJS Open 2021;5:zraa033. [PMID: 33609389 DOI: 10.1093/bjsopen/zraa033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Guinan EM, Bennett AE, Doyle SL, O'Neill L, Gannon J, Foley G, Elliott JA, O'Sullivan J, Reynolds JV, Hussey J. Measuring the impact of oesophagectomy on physical functioning and physical activity participation: a prospective study. BMC Cancer 2019;19:682. [PMID: 31299920 DOI: 10.1186/s12885-019-5888-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
292 Visser E, Leeftink AG, van Rossum PS, Siesling S, van Hillegersberg R, Ruurda JP. Waiting Time from Diagnosis to Treatment has no Impact on Survival in Patients with Esophageal Cancer. Ann Surg Oncol 2016;23:2679-89. [PMID: 27012988 DOI: 10.1245/s10434-016-5191-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
293 So TH, Chan SK, Chan WL, Choi H, Chiang CL, Lee V, Lam TC, Wong I, Law S, Kwong D, Ming Spring Kong F, Jin JY, Lam KO. Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma. Adv Radiat Oncol 2020;5:880-8. [PMID: 33089018 DOI: 10.1016/j.adro.2020.03.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
294 Liu T, Ding S, Dang J, Wang H, Chen J, Li G. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. Radiat Oncol 2019;14:176. [PMID: 31619265 DOI: 10.1186/s13014-019-1388-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
295 Zhang B, Xiao Q, Yang D, Li X, Hu J, Wang Y, Wang W. Spindle cell carcinoma of the esophagus: A multicenter analysis in comparison with typical squamous cell carcinoma. Medicine (Baltimore). 2016;95:e4768. [PMID: 27631227 DOI: 10.1097/md.0000000000004768] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
296 Housman B, Flores R, Lee DS. Narrative review of anxiety and depression in patients with esophageal cancer: underappreciated and undertreated. J Thorac Dis 2021;13:3160-70. [PMID: 34164206 DOI: 10.21037/jtd-20-3529] [Reference Citation Analysis]
297 Kawakita Y, Motoyama S, Sato Y, Wakita A, Nagaki Y, Imai K, Minamiya Y. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy. World J Surg 2020;44:1559-68. [PMID: 31907570 DOI: 10.1007/s00268-019-05344-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
298 Koyanagi K, Kanamori K, Ninomiya Y, Yatabe K, Higuchi T, Yamamoto M, Tajima K, Ozawa S. Progress in Multimodal Treatment for Advanced Esophageal Squamous Cell Carcinoma: Results of Multi-Institutional Trials Conducted in Japan. Cancers (Basel) 2020;13:E51. [PMID: 33375499 DOI: 10.3390/cancers13010051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. J Clin Oncol 2021;39:2803-15. [PMID: 34077237 DOI: 10.1200/JCO.20.03611] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
300 Martín-Richard M, Carmona-Bayonas A, Custodio AB, Gallego J, Jiménez-Fonseca P, Reina JJ, Richart P, Rivera F, Alsina M, Sastre J. SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clin Transl Oncol 2020;22:236-44. [PMID: 31989475 DOI: 10.1007/s12094-019-02259-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
301 Hosoda K, Niihara M, Harada H, Yamashita K, Hiki N. Robot-assisted minimally invasive esophagectomy for esophageal cancer: Meticulous surgery minimizing postoperative complications. Ann Gastroenterol Surg 2020;4:608-17. [PMID: 33319150 DOI: 10.1002/ags3.12390] [Reference Citation Analysis]
302 Mao Y, Yu Z, You B, Fang W, Badgwell B, Berry MF, Ceppa DP, Chen C, Chen H, Cuesta MA, D'Journo XB, Eslick GD, Fu J, Fu X, Gao S, He J, He J, Huang Y, Jiang G, Jiang Z, Kim JY, Li D, Li H, Li S, Liu D, Liu L, Liu Y, Li X, Li Y, Mao W, Molena D, Morse CR, Novoa NM, Tan L, Tan Q, Toker A, Tong T, Wang Q, Weksler B, Xu L, Xu S, Yan T, Zhang L, Zhang X, Zhang X, Zhang Z, Zhi X, Zhou Q. Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma. J Thorac Dis 2019;11:319-28. [PMID: 30863610 DOI: 10.21037/jtd.2018.12.07] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
303 Kijima T, Nakagawa H, Shimonosono M, Chandramouleeswaran PM, Hara T, Sahu V, Kasagi Y, Kikuchi O, Tanaka K, Giroux V, Muir AB, Whelan KA, Ohashi S, Naganuma S, Klein-Szanto AJ, Shinden Y, Sasaki K, Omoto I, Kita Y, Muto M, Bass AJ, Diehl JA, Ginsberg GG, Doki Y, Mori M, Uchikado Y, Arigami T, Avadhani NG, Basu D, Rustgi AK, Natsugoe S. Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. Cell Mol Gastroenterol Hepatol 2019;7:73-91. [PMID: 30510992 DOI: 10.1016/j.jcmgh.2018.09.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
304 Li N, Zhao Z, Liu P, Zheng Y, Cai S, Sun Y, Wang B. Upregulation of deubiquitinase USP7 by transcription factor FOXO6 promotes EC progression via targeting the JMJD3/CLU axis. Mol Ther Oncolytics 2021;20:583-95. [PMID: 33768140 DOI: 10.1016/j.omto.2020.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
305 Wang B, Song H, Jiang H, Fu Y, Ding X, Zhou C. Early diagnostic potential of APC hypermethylation in esophageal cancer. Cancer Manag Res 2018;10:181-98. [PMID: 29440928 DOI: 10.2147/CMAR.S148677] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
306 Hale MD, Nankivell M, Hutchins GG, Stenning SP, Langley RE, Mueller W, West NP, Wright AI, Treanor D, Hewitt LC, Allum WH, Cunningham D, Hayden JD, Grabsch HI. Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Oncotarget 2016;7:77565-75. [PMID: 27769054 DOI: 10.18632/oncotarget.12723] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
307 Zhou YJ, Lu XF, Meng JL, Wang XY, Zhang QW, Chen JN, Wang QW, Yan FR, Li XB. Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis. BMC Cancer 2021;21:771. [PMID: 34217249 DOI: 10.1186/s12885-021-08534-9] [Reference Citation Analysis]
308 Zhang C, Luo Y, Zhang Z, Zhang Z, Zhang G, Wang F, Che Y, Fang L, Zhang Y, Sun N, He J. Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes. Front Cell Dev Biol 2020;8:580005. [PMID: 33392181 DOI: 10.3389/fcell.2020.580005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Defize IL, van der Horst S, Bülbul M, Haj Mohammad N, Mook S, Meijer GJ, Brosens LAA, Ruurda JP, van Hillegersberg R. Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) for T4b Esophageal Cancer After Definitive Chemoradiotherapy. Ann Surg Oncol 2021;28:2730-8. [PMID: 33341917 DOI: 10.1245/s10434-020-09425-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
310 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1-24. [PMID: 30171413 DOI: 10.1007/s10388-018-0641-9] [Cited by in Crossref: 138] [Cited by in F6Publishing: 98] [Article Influence: 46.0] [Reference Citation Analysis]
311 Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget 2019;10:4703-18. [PMID: 31384397 DOI: 10.18632/oncotarget.27095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
312 Sodergren MH, Mangal N, Wasan H, Sadanandam A, Balachandran VP, Jiao LR, Habib N. Immunological combination treatment holds the key to improving survival in pancreatic cancer. J Cancer Res Clin Oncol 2020;146:2897-911. [PMID: 32748119 DOI: 10.1007/s00432-020-03332-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
313 Schokker S, van der Woude SO, van Kleef JJ, van Zoen DJ, van Oijen MGH, Mearadji B, Beenen LFM, Stroes CI, Waasdorp C, Jibodh RA, Creemers A, Meijer SL, Hooijer GKJ, Punt CJA, Bijlsma MF, van Laarhoven HWM. Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). Cancers (Basel) 2019;11:E827. [PMID: 31207904 DOI: 10.3390/cancers11060827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
314 Goetze TO, Al-Batran SE, Berlth F, Hoelscher AH. Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective. J Gastric Cancer 2019;19:148-56. [PMID: 31245159 DOI: 10.5230/jgc.2019.19.e19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
315 Toxopeus E, Lynam-Lennon N, Biermann K, Dickens G, de Ruiter PE, van Lanschot J, Reynolds JV, Wijnhoven B, O'Sullivan J, van der Laan L. Tumor microRNA-126 controls cell viability and associates with poor survival in patients with esophageal adenocarcinoma. Exp Biol Med (Maywood) 2019;244:1210-9. [PMID: 31390899 DOI: 10.1177/1535370219868671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
316 Loeser H, Scholz M, Fuchs H, Essakly A, Damanakis AI, Zander T, Büttner R, Schröder W, Bruns C, Quaas A, Gebauer F. Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival. Sci Rep 2020;10:18411. [PMID: 33110104 DOI: 10.1038/s41598-020-75085-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Fu Y, Wang PP, He D, Zheng Y, Ding ZY. Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report. Thorac Cancer 2021;12:1234-9. [PMID: 33619875 DOI: 10.1111/1759-7714.13905] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
318 Steenhagen E. Preoperative nutritional optimization of esophageal cancer patients. J Thorac Dis 2019;11:S645-53. [PMID: 31080641 DOI: 10.21037/jtd.2018.11.33] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
319 Wong C, Law S. Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer. J Thorac Dis 2017;9:S773-80. [PMID: 28815073 DOI: 10.21037/jtd.2017.04.29] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
320 Markar SR, Gronnier C, Pasquer A, Duhamel A, Behal H, Théreaux J, Gagnière J, Lebreton G, Brigand C, Renaud F, Piessen G, Meunier B, Collet D, Mariette C; FREGAT Working Group—FRENCH—AFC. Discrepancy Between Clinical and Pathologic Nodal Status of Esophageal Cancer and Impact on Prognosis and Therapeutic Strategy. Ann Surg Oncol 2017;24:3911-20. [PMID: 28948524 DOI: 10.1245/s10434-017-6088-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
321 Wang X, Wang H, Wang H, Huang J, Wang X, Jiang Z, Tan L, Jiang D, Hou Y. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery. BMC Cancer 2021;21:111. [PMID: 33535987 DOI: 10.1186/s12885-020-07779-0] [Reference Citation Analysis]
322 Toxopeus E, van der Schaaf M, van Lanschot J, Lagergren J, Lagergren P, van der Gaast A, Wijnhoven B. Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS). Ann Surg Oncol. 2018;25:2441-2448. [PMID: 29948420 DOI: 10.1245/s10434-018-6554-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
323 Zeng Y, Yu W, Liu Q, Yu WW, Zhu ZF, Zhao WX, Liu J, Wang JM, Fu XL, Liu Y, Cai XW. Difference in failure patterns of pT3-4N0-3M0 esophageal cancer treated by surgery vs surgery plus radiotherapy. World J Gastrointest Oncol 2019;11:1172-81. [PMID: 31908722 DOI: 10.4251/wjgo.v11.i12.1172] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
324 Soror T, Kho G, Zhao KL, Ismail M, Badakhshi H. Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Dis 2018;10:4069-76. [PMID: 30174850 DOI: 10.21037/jtd.2018.06.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
325 Ye Z, Zhao H, Zhou W, Ye T, Geng C, Li X, Yuan L, Du M, Xu H, Wang Q. Lower Serum Matrix Metalloproteinase‑9 in Metastatic Patients with Esophageal Squamous Cell Carcinoma After Concurrent Radiotherapy Was Significant for Prognosis. Onco Targets Ther 2020;13:12857-66. [PMID: 33364781 DOI: 10.2147/OTT.S280791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
326 Capovilla G, Moletta L, Pierobon ES, Salvador R, Provenzano L, Zanchettin G, Costantini M, Merigliano S, Valmasoni M. Optimal Treatment of cT2N0 Esophageal Carcinoma: Is Upfront Surgery Really the Way? Ann Surg Oncol 2021. [PMID: 34142286 DOI: 10.1245/s10434-021-10194-9] [Reference Citation Analysis]
327 Khan M, Urooj N, Syed AA, Khattak S, Kazmi A, Ashraf MI, Batool S. Prognostic Factors for Recurrence in Esophageal Cancer Patients Treated With Neoadjuvant Therapy and Surgery: A Single-institution Analysis. Cureus 2020;12:e8108. [PMID: 32542161 DOI: 10.7759/cureus.8108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Abboud HS, Camuzi D, Rapozo DC, Fernandes PV, Nicolau-Neto P, Guaraldi S, Simão TA, Ribeiro Pinto LF, Gonzaga IM, Soares-Lima SC. MET overexpression and intratumor heterogeneity in esophageal squamous cell carcinoma. Braz J Med Biol Res 2021;54:e10877. [PMID: 34037097 DOI: 10.1590/1414-431X2020e10877] [Reference Citation Analysis]
329 Xie CY, Pang CL, Chan B, Wong EY, Dou Q, Vardhanabhuti V. Machine Learning and Radiomics Applications in Esophageal Cancers Using Non-Invasive Imaging Methods-A Critical Review of Literature. Cancers (Basel) 2021;13:2469. [PMID: 34069367 DOI: 10.3390/cancers13102469] [Reference Citation Analysis]
330 Zhang W, Li Y, Xue L, Qu D, Jiang Z, Wang Z, Yang Z, Zhou A. Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study. Cancer Manag Res 2021;13:2163-70. [PMID: 33688259 DOI: 10.2147/CMAR.S298360] [Reference Citation Analysis]
331 Gibson MK, Catalano P, Kleinberg LR, Staley CA 3rd, Montgomery EA, Jimeno A, Song WF, Mulcahy MF, Leichman LP, Benson AB 3rd. Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205). Oncologist 2020;25:e53-9. [PMID: 31227647 DOI: 10.1634/theoncologist.2018-0750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
332 Jomrich G, Hollenstein M, John M, Ristl R, Paireder M, Kristo I, Asari R, Schoppmann SF. High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma. Ann Surg Oncol 2019;26:976-85. [PMID: 30706229 DOI: 10.1245/s10434-019-07186-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
333 Chen J, Liu Q, Zhang X, Yang H, Tan Z, Lin Y, Fu J. Comparisons of short-term outcomes between robot-assisted and thoraco-laparoscopic esophagectomy with extended two-field lymph node dissection for resectable thoracic esophageal squamous cell carcinoma. J Thorac Dis 2019;11:3874-80. [PMID: 31656660 DOI: 10.21037/jtd.2019.09.05] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
334 Hoeppner J, Plum PS, Buhr H, Gockel I, Lorenz D, Ghadimi M, Bruns C; Qualitätskommission der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie. [Surgical treatment of esophageal cancer-Indicators for quality in diagnostics and treatment]. Chirurg 2021;92:350-60. [PMID: 32876700 DOI: 10.1007/s00104-020-01267-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
335 den Bakker CM, Smit JK, Bruynzeel AME, van Grieken NCT, Daams F, Derks S, Cuesta MA, Plukker JTM, van der Peet DL. Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary. J Thorac Dis 2017;9:S843-50. [PMID: 28815082 DOI: 10.21037/jtd.2017.06.123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
336 Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A, Imamura Y. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today 2020;50:12-20. [PMID: 31535225 DOI: 10.1007/s00595-019-01878-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 20.0] [Reference Citation Analysis]
337 Allen CJ, Blumenthaler AN, Smith GL, Das P, Minsky BD, Blum M, Ajani J, Mansfield PF, Ikoma N, Badgwell BD. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Ann Surg Oncol 2021;28:758-65. [PMID: 32696305 DOI: 10.1245/s10434-020-08864-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Zhao Q, Chen S, Feng JF. A novel inflammation-based prognostic index for patients with esophageal squamous cell carcinoma: neutrophil lymphocyte ratio/albumin ratio. Oncotarget 2017;8:103535-42. [PMID: 29262582 DOI: 10.18632/oncotarget.21989] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
339 Koch OO, Weitzendorfer M, Varga M, Tschoner A, Partl R, Perathoner A, Gehwolf P, Kapp KS, Függer R, Öfner D, Emmanuel K. Perioperative chemotherapy versus neoadjuvant chemoradiation for patients with adenocarcinoma of the distal esophagus in Austria: a retrospective analysis. World J Surg Oncol 2019;17:146. [PMID: 31426805 DOI: 10.1186/s12957-019-1693-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
340 Li J, Zhao Q, Ge X, Song Y, Tian Y, Wang S, Liu M, Qiao X. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis. BMC Surg 2021;21:137. [PMID: 33731072 DOI: 10.1186/s12893-021-01136-z] [Reference Citation Analysis]
341 Vollenbrock SE, Nowee ME, Voncken FEM, Kotte ANTJ, Goense L, van Rossum PSN, van Lier ALHMW, Heijmink SW, Bartels-Rutten A, Wessels FJ, Aleman BMP, Dewit L, Kerkmeijer LGW, Jansen EPM, Intven M, Lips IM, Meijer GJ, Nijkamp J. Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT. Adv Radiat Oncol 2019;4:596-604. [PMID: 31673653 DOI: 10.1016/j.adro.2019.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
342 Park SY, Hong MH, Kim HR, Lee CG, Cho JH, Cho BC, Kim DJ. The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma. J Thorac Dis 2020;12:6426-34. [PMID: 33282345 DOI: 10.21037/jtd-20-1088] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
343 Duarte MBO, Pereira EB, Lopes LR, Andreollo NA, Carvalheira JBC. Chemoradiotherapy With or Without Surgery for Esophageal Squamous Cancer According to Hospital Volume. JCO Glob Oncol 2020;6:828-36. [PMID: 32552112 DOI: 10.1200/JGO.19.00360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
344 Hagens ERC, Feenstra ML, van Egmond MA, van Laarhoven HWM, Hulshof MCCM, Boshier PR, Low DE, van Berge Henegouwen MI, Gisbertz SS. Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment. J Cachexia Sarcopenia Muscle 2020;11:756-67. [PMID: 32096923 DOI: 10.1002/jcsm.12540] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
345 Aytaç E, Aslan F, Çicek B, Erdamar S, Gürses B, Güven K, Falay O, Karahasanoğlu T, Selçukbiricik F, Selek U, Atalar B, Balık E, Tözün N, Rozanes İ, Arıcan A, Hamzaoğlu İ, Baca B, Molinas Mandel N, Saruç M, Göksel S, Demir G, Ağaoğlu F, Yakıcıer C, Özbek U, Özben V, Özyar E, Güner AL, Er Ö, Kaban K, Bölükbaşı Y, Buğra D, Group Tİ. Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group. Turk J Gastroenterol 2019;30:584-98. [PMID: 30541724 DOI: 10.5152/tjg.2018.18737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Sun HB, Xing WQ, Liu XB, Zheng Y, Yang SJ, Wang ZF, Liu SL, Ba YF, Zhang RX, Liu BX, Fan CC, Chen PN, Liang GH, Yu YK, Liu Q, Wang HR, Li HM, Li ZX; written on Henan Cancer Hospital Thoracic Oncology Group (HCHTOG). Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903). BMC Cancer 2020;20:303. [PMID: 32293362 DOI: 10.1186/s12885-020-06824-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
347 Kuwayama N, Hoshino I, Gunji H, Kurosaki T, Tonooka T, Soda H, Sonoda I, Eto R, Takiguchi N, Nabeya Y, Itami M, Takayama W. CA19-9-producing esophageal adenocarcinoma originating from the esophageal cardia of the mid-thoracic esophagus: a case report. Surg Case Rep 2021;7:166. [PMID: 34264404 DOI: 10.1186/s40792-021-01252-1] [Reference Citation Analysis]
348 Markar SR, Griffiths EA, Behrens P, Singh P, Vohra RS, Gossage J, Underwood T, Hanna GB; LASORS study group. Protocol for LAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study. BMJ Open 2020;10:e034897. [PMID: 32499265 DOI: 10.1136/bmjopen-2019-034897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
349 Powell AGMT, Karran A, Blake P, Christian A, Roberts SA, Lewis WG. Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy. BJS Open 2020;4:593-600. [PMID: 32374504 DOI: 10.1002/bjs5.50287] [Reference Citation Analysis]
350 Xu H, Zhang L, Miao J, Liu S, Liu H, Jia T, Zhang Q. Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study. World J Surg Oncol 2020;18:144. [PMID: 32593312 DOI: 10.1186/s12957-020-01917-5] [Reference Citation Analysis]
351 Liu T, Liu W, Zhang H, Ren C, Chen J, Dang J. The role of postoperative radiotherapy for radically resected esophageal squamous cell carcinoma: a systemic review and meta-analysis. J Thorac Dis 2018;10:4403-12. [PMID: 30174889 DOI: 10.21037/jtd.2018.06.65] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
352 de Pascale S, Parise P, Valmasoni M, Weindelmayer J, Terraneo F, Cella CA, Giacopuzzi S, Cossu A, Massaron S, Elmore U, Merigliano S, Fumagalli Romario U, On Behalf Of The Italian Society For The Study Of Esophageal Diseases Sisme. Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis. Cancers (Basel) 2021;13:666. [PMID: 33562316 DOI: 10.3390/cancers13040666] [Reference Citation Analysis]
353 Xiang M, Chang DT, Heestand GM, Pollom EL. Survival after neoadjuvant approaches to gastroesophageal junction cancer. Gastric Cancer 2020;23:175-83. [PMID: 31230228 DOI: 10.1007/s10120-019-00980-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
354 Münch S, Heinrich C, Habermehl D, Oechsner M, Combs SE, Duma MN. Primary radio(chemo)therapy for esophageal cancer in elderly patients: are efficiency and toxicity comparable with younger patients? Eur J Med Res 2017;22:24. [PMID: 28683820 DOI: 10.1186/s40001-017-0265-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
355 Slooter MD, de Bruin DM, Eshuis WJ, Veelo DP, van Dieren S, Gisbertz SS, van Berge Henegouwen MI. Quantitative fluorescence-guided perfusion assessment of the gastric conduit to predict anastomotic complications after esophagectomy. Dis Esophagus. 2021;34. [PMID: 33016305 DOI: 10.1093/dote/doaa100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
356 Ashok A, Niyogi D, Ranganathan P, Tandon S, Bhaskar M, Karimundackal G, Jiwnani S, Shetmahajan M, Pramesh CS. The enhanced recovery after surgery (ERAS) protocol to promote recovery following esophageal cancer resection. Surg Today 2020;50:323-34. [PMID: 32048046 DOI: 10.1007/s00595-020-01956-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
357 Koldby KM, Mortensen MB, Detlefsen S, Pfeiffer P, Thomassen M, Kruse TA. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. J Gastroenterol 2019;54:108-21. [PMID: 30242476 DOI: 10.1007/s00535-018-1508-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
358 Kuvendjiska J, Bronsert P, Martini V, Lang S, Pitman MB, Hoeppner J, Kulemann B. Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment. Cancers (Basel) 2019;11:E397. [PMID: 30901891 DOI: 10.3390/cancers11030397] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
359 Chen H, Zhou L, Yang Y, Yang L, Chen L. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma. Med Sci Monit 2018;24:4183-91. [PMID: 29915168 DOI: 10.12659/MSM.910326] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
360 Gao HJ, Shang XB, Gong L, Zhang HD, Ren P, Shi GD, Wei YC, Yu ZT. Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysis. Thorac Cancer 2020;11:243-52. [PMID: 31828980 DOI: 10.1111/1759-7714.13235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
361 Keung EZ, Ukponmwan EU, Cogdill AP, Wargo JA. The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Ann Surg Oncol 2018;25:1814-27. [PMID: 29500764 DOI: 10.1245/s10434-018-6379-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
362 Franco P, Arcadipane F, Strignano P, Spadi R, Trino E, Martini S, Iorio GC, Satolli MA, Airoldi M, Romagnoli R, Camandona M, Ricardi U. Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials. Med Oncol 2017;34:40. [PMID: 28176241 DOI: 10.1007/s12032-017-0898-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
363 Tully R, Loughney L, Bolger J, Sorensen J, McAnena O, Collins CG, Carroll PA, Arumugasamy M, Murphy TJ, Robb WB; PERIOP OG Working Group. The effect of a pre- and post-operative exercise programme versus standard care on physical fitness of patients with oesophageal and gastric cancer undergoing neoadjuvant treatment prior to surgery (The PERIOP-OG Trial): Study protocol for a randomised controlled trial. Trials 2020;21:638. [PMID: 32660526 DOI: 10.1186/s13063-020-04311-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
364 Ji W, Wang J, Zhou R, Wang M, Wang W, Pang P, Kong M, Zhou C. Diagnostic Performance of Vascular Permeability and Texture Parameters for Evaluating the Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma. Front Oncol 2021;11:604480. [PMID: 34084740 DOI: 10.3389/fonc.2021.604480] [Reference Citation Analysis]
365 van Rossum PSN, Xu C, Fried DV, Goense L, Court LE, Lin SH. The emerging field of radiomics in esophageal cancer: current evidence and future potential. Transl Cancer Res 2016;5:410-23. [PMID: 30687593 DOI: 10.21037/tcr.2016.06.19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
366 Wald O, Smaglo B, Mok H, Groth SS. Future directions in esophageal cancer therapy. Ann Cardiothorac Surg 2017;6:159-66. [PMID: 28447005 DOI: 10.21037/acs.2017.02.01] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
367 Yang L, Shen C, Pettit CJ, Li T, Hu AJ, Miller ED, Zhang J, Lin SH, Williams TM. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy. Clin Cancer Res 2020;26:3740-50. [PMID: 32220892 DOI: 10.1158/1078-0432.CCR-19-3373] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
368 Rice TW, Lu M, Ishwaran H, Blackstone EH; Worldwide Esophageal Cancer Collaboration Investigators. Precision Surgical Therapy for Adenocarcinoma of the Esophagus and Esophagogastric Junction. J Thorac Oncol. 2019;14:2164-2175. [PMID: 31442498 DOI: 10.1016/j.jtho.2019.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
369 Yang S, Wang P, Wang S, Cong A, Zhang Q, Shen W, Li X, Zhang W, Han G. miRNA-181a-5p Enhances the Sensitivity of Cells to Cisplatin in Esophageal Adenocarcinoma by Targeting CBLB. Cancer Manag Res 2020;12:4981-90. [PMID: 32612385 DOI: 10.2147/CMAR.S251264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
370 Ono T, Wada H, Ishikawa H, Tamamura H, Tokumaru S. Proton beam therapy is a safe and effective treatment in elderly patients with esophageal squamous cell carcinoma. Thorac Cancer 2020;11:2170-7. [PMID: 32510875 DOI: 10.1111/1759-7714.13524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
371 Oh D, Kim JH. The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Korean J Thorac Cardiovasc Surg 2020;53:160-7. [PMID: 32793446 DOI: 10.5090/kjtcs.2020.53.4.160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
372 Xu HT, Miao J, Liu JW, Zhang LG, Zhang QG. Prognostic value of circulating tumor cells in esophageal cancer. World J Gastroenterol 2017;23:1310-8. [PMID: 28275311 DOI: 10.3748/wjg.v23.i7.1310] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
373 Markar SR, Lagergren J. Surgical and Surgeon-Related Factors Related to Long-Term Survival in Esophageal Cancer: A Review. Ann Surg Oncol 2020;27:718-23. [PMID: 31691111 DOI: 10.1245/s10434-019-07966-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
374 Li X, Xu J, Zhu L, Yang S, Yu L, Lv W, Hu J. A novel nomogram with preferable capability in predicting the overall survival of patients after radical esophageal cancer resection based on accessible clinical indicators: A comparison with AJCC staging. Cancer Med 2021;10:4228-39. [PMID: 34128338 DOI: 10.1002/cam4.3878] [Reference Citation Analysis]
375 Ikoma N, Cormier JN, Feig B, Du XL, Yamal JM, Hofstetter W, Das P, Ajani JA, Roland CL, Fournier K. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. Cancer. 2018;124:998-1007. [PMID: 29393964 DOI: 10.1002/cncr.31155] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
376 Fontana E, Smyth EC, Cunningham D. Esophagogastric Adenocarcinoma: Is More Chemotherapy Better? Curr Treat Options Oncol 2016;17:21. [PMID: 27032643 DOI: 10.1007/s11864-016-0395-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
377 Steins A, Ebbing EA, Creemers A, van der Zalm AP, Jibodh RA, Waasdorp C, Meijer SL, van Delden OM, Krishnadath KK, Hulshof MCCM, Bennink RJ, Punt CJA, Medema JP, Bijlsma MF, van Laarhoven HWM. Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma. Int J Cancer 2019;145:2792-803. [PMID: 31018252 DOI: 10.1002/ijc.32364] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
378 Borggreve AS, Heethuis SE, Boekhoff MR, Goense L, van Rossum PSN, Brosens LAA, van Lier ALHMW, van Hillegersberg R, Lagendijk JJW, Mook S, Ruurda JP, Meijer GJ. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer. Eur Radiol 2020;30:1896-907. [PMID: 31822974 DOI: 10.1007/s00330-019-06513-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
379 Zhang S, Tan Y, Cai X, Luo K, Wu Z, Lu J. Preoperative weight loss is associated with poorer prognosis in operable esophageal cancer patients: A single-center retrospective analysis of a large cohort of Chinese patients. J Cancer 2020;11:1994-9. [PMID: 32194811 DOI: 10.7150/jca.40344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
380 Hu Y, Xie C, Yang H, Ho JWK, Wen J, Han L, Chiu KWH, Fu J, Vardhanabhuti V. Assessment of Intratumoral and Peritumoral Computed Tomography Radiomics for Predicting Pathological Complete Response to Neoadjuvant Chemoradiation in Patients With Esophageal Squamous Cell Carcinoma. JAMA Netw Open. 2020;3:e2015927. [PMID: 32910196 DOI: 10.1001/jamanetworkopen.2020.15927] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
381 Lordick F, Gockel I. Chances, risks and limitations of neoadjuvant therapy in surgical oncology. Innov Surg Sci 2016;1:3-11. [PMID: 31579713 DOI: 10.1515/iss-2016-0004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
382 Zhang X, Yang Y, Sun Y, Ye B, Guo X, Mao T, Hua R, Li B, Gu H, Liu J, Li Z. Adjuvant therapy for pathological T3N0M0 esophageal squamous cell carcinoma. J Thorac Dis 2019;11:2512-22. [PMID: 31372288 DOI: 10.21037/jtd.2019.05.70] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
383 Goense L, Meziani J, van Rossum PSN, Wessels FJ, Lam MGEH, van Hillegersberg R, Ruurda JP. Cervical ultrasonography has no additional value over negative 18F-FDG PET/CT scans for diagnosing cervical lymph node metastases in patients with oesophageal cancer. Eur Radiol 2018;28:2031-7. [PMID: 29218619 DOI: 10.1007/s00330-017-5136-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
384 Laxague F, Schlottmann F. Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy? World J Clin Oncol 2021;12:557-64. [PMID: 34367928 DOI: 10.5306/wjco.v12.i7.557] [Reference Citation Analysis]
385 Greally M, Ku GY. Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical. J Thorac Dis 2019;11:S1855-60. [PMID: 31632768 DOI: 10.21037/jtd.2019.08.116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
386 Krishnamurthy A, Behuria SS. Demographic Trends in Carcinoma Esophagus from India along with a Brief Comparative Review of the Global Trends. South Asian J Cancer 2020;9:163-7. [PMID: 33937139 DOI: 10.1055/s-0041-1723103] [Reference Citation Analysis]
387 Kumar T, Pai E, Singh R, Francis NJ, Pandey M. Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World J Surg Oncol 2020;18:59. [PMID: 32199464 DOI: 10.1186/s12957-020-01830-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
388 Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao R. Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Ann Surg Oncol 2021;28:663-75. [PMID: 32648178 DOI: 10.1245/s10434-020-08761-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
389 Ku GY, Bains MS, Park DJ, Janjigian YY, Rusch VW, Rizk NP, Yoon SS, Millang B, Capanu M, Goodman KA, Ilson DH. Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. J Gastrointest Oncol 2016;7:828-37. [PMID: 28078107 DOI: 10.21037/jgo.2016.08.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
390 Moentenich V, Gebauer F, Comut E, Tuchscherer A, Bruns C, Schroeder W, Buettner R, Alakus H, Loeser H, Zander T, Quaas A. Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies. Oncol Lett 2020;19:3665-70. [PMID: 32391091 DOI: 10.3892/ol.2020.11520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
391 Ni W, Chen J, Xiao Z, Yu S, Zhang W, Zhou Z, Chen D, Feng Q, Chen X, Lin Y, Zhu K, Gao S, Xue Q, Mao Y, Cheng G, Sun K, Liu X, Fang D. Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two-center study. Thorac Cancer 2019;10:1431-40. [PMID: 31102336 DOI: 10.1111/1759-7714.13088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
392 Huang C, Huang D, Zhu Y, Xie G, Wang H, Shi J, Jia B, Yuan Y, Zhang W. Comparison of a Concurrent Fluorouracil-Based Regimen and a Taxane-Based Regimen Combined with Radiotherapy in Elderly Patients with Esophageal Squamous Cell Carcinoma. Transl Oncol 2020;13:100736. [PMID: 32092670 DOI: 10.1016/j.tranon.2019.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
393 Plum PS, Löser H, Zander T, Essakly A, Bruns CJ, Hillmer AM, Alakus H, Schröder W, Büttner R, Gebauer F, Quaas A. GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy. J Cancer Res Clin Oncol 2021;147:1031-40. [PMID: 33300112 DOI: 10.1007/s00432-020-03486-2] [Reference Citation Analysis]
394 Goense L, Stassen PMC, Wessels FJ, van Rossum PSN, Ruurda JP, van Leeuwen MS, van Hillegersberg R. Diagnostic performance of a CT-based scoring system for diagnosis of anastomotic leakage after esophagectomy: comparison with subjective CT assessment. Eur Radiol 2017;27:4426-34. [PMID: 28357496 DOI: 10.1007/s00330-017-4802-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
395 Davidson M, Chau I, Cunningham D, Khabra K, Iveson T, Hickish T, Seymour M, Starling N. Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World J Gastrointest Oncol 2017;9:333-40. [PMID: 28868114 DOI: 10.4251/wjgo.v9.i8.333] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
396 Batool S, Khan M, Akbar SA, Ashraf I. Risk factors and patterns of recurrence after curative resection in Gastroesophageal Junction Adenocarcinoma. Pak J Med Sci 2019;35:1276-83. [PMID: 31488992 DOI: 10.12669/pjms.35.5.963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
397 Lyu J, Liu T, Li T, Li F, Wang Q, Wang J, Han Y, Wang J, Zhang J, Peng L, Lang J. Comparison  of  efficacy, safety, and costs between neoadjuvant hypofractionated radiotherapy and conventionally fractionated radiotherapy for esophageal carcinoma. Cancer Med 2019;8:3710-8. [PMID: 31119872 DOI: 10.1002/cam4.2250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
398 Stroes CI, Schokker S, Creemers A, Molenaar RJ, Hulshof MCCM, van der Woude SO, Bennink RJ, Mathôt RAA, Krishnadath KK, Punt CJA, Verhoeven RHA, van Oijen MGH, Creemers GJ, Nieuwenhuijzen GAP, van der Sangen MJC, Beerepoot LV, Heisterkamp J, Los M, Slingerland M, Cats A, Hospers GAP, Bijlsma MF, van Berge Henegouwen MI, Meijer SL, van Laarhoven HWM. Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. J Clin Oncol 2020;38:462-71. [PMID: 31809243 DOI: 10.1200/JCO.19.01814] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
399 Lee SL, Bassetti M, Meijer GJ, Mook S. Review of MR-Guided Radiotherapy for Esophageal Cancer. Front Oncol 2021;11:628009. [PMID: 33828980 DOI: 10.3389/fonc.2021.628009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
400 Schlößer HA, Thelen M, Lechner A, Wennhold K, Garcia-Marquez MA, Rothschild SI, Staib E, Zander T, Beutner D, Gathof B, Gilles R, Cukuroglu E, Göke J, Shimabukuro-Vornhagen A, Drebber U, Quaas A, Bruns CJ, Hölscher AH, Von Bergwelt-Baildon MS. B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies. Oncoimmunology 2019;8:e1512458. [PMID: 30546950 DOI: 10.1080/2162402X.2018.1512458] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
401 de Heer EC, Hulshoff JB, Klerk D, Burgerhof JGM, de Groot DJA, Plukker JTM, Hospers GAP. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer. Ann Surg Oncol 2017;24:1811-20. [PMID: 28188501 DOI: 10.1245/s10434-017-5797-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
402 Feng JF, Wang L, Jiang YH, Yang X. C-Reactive Protein to Prealbumin Ratio (CPR): A Novel Inflammatory-Nutritional Prognostic Factor for Predicting Cancer-Specific Survival (CSS) and Overall Survival (OS) in Patients with Resectable Esophageal Squamous Cell Carcinoma. J Oncol 2019;2019:4359103. [PMID: 31379941 DOI: 10.1155/2019/4359103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
403 Rahimy E, Koong A, Toesca D, White MN, Panjwani N, Fisher G, Chang D, Pollom E. Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review. Adv Radiat Oncol 2020;5:1188-96. [PMID: 33305080 DOI: 10.1016/j.adro.2020.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Wang J, Qin J, Jing S, Liu Q, Cheng Y, Wang Y, Cao F. Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta-analysis. Thorac Cancer 2018;9:1638-47. [PMID: 30277016 DOI: 10.1111/1759-7714.12874] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
405 Duan XF, Yue J, Tang P, Shang XB, Jiang HJ, Yu ZT. Lymph node dissection for Siewert II esophagogastric junction adenocarcinoma: A retrospective study of 3 surgical procedures. Medicine (Baltimore) 2017;96:e6120. [PMID: 28207537 DOI: 10.1097/MD.0000000000006120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
406 Kuo YH, Fang HY, Lin YS, Lein MY, Yang CY, Ho SC, Li CC, Chien CR. Effectiveness of image-guided radiotherapy for locally advanced esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy. Thorac Cancer 2020;11:113-9. [PMID: 31742897 DOI: 10.1111/1759-7714.13244] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
407 Schiffmann LM, Loeser H, Jacob AS, Maus M, Fuchs H, Zhao Y, Tharun L, Essakly A, Iannos Damanakis A, Zander T, Büttner R, Schröder W, Bruns C, Quaas A, Gebauer F. Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal Adenocarcinoma. Cancers (Basel) 2020;12:E451. [PMID: 32075129 DOI: 10.3390/cancers12020451] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
408 de Jongh M, Eyck BM, van der Werf LR, Toxopeus ELA, van Lanschot JJB, Lagarde SM, van der Gaast A, Nuyttens J, Wijnhoven BPL. Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. BJS Open 2021;5:zrab022. [PMID: 33876211 DOI: 10.1093/bjsopen/zrab022] [Reference Citation Analysis]